Archive for May, 2020

COLUMBIA, Md., May 15, 2020 /PRNewswire/ -- The Foundation Fighting Blindness, the world's leading organization searching for treatments and cures for inherited retinal diseases, has introduced many improvements and upgrades to its My Retina Tracker Registry. Overall, the upgraded platform makes this best-in-class patient database even easier to use for patients, industry, and investigators who access de-identified data for research studies and clinical trial recruitment. Launched in 2013, more than 15,500 IRD patients are active in the Registry. The patient-driven registry is accessible at MyRetinaTracker.org.

"The My Retina Tracker Registry has been an invaluable resource for both IRD patients and research communities. It provides a secure venue for patients to get on the radar screens of therapy developers both industry and researcher partners who are recruiting for clinical trials and conducting studies using human data," says Brian Mansfield, PhD, executive vice president of research and interim chief scientific officer. "From the start, we have been strongly committed to security of privacy coupled with ease-of-use for both patients and professionals. These enhancements are part of our continual process to maximize the registry's usability and efficiently integrate it with our genetic testing programs."

Highlights of upgrades and enhancements:

The Foundation also offers no-cost genetic testing for those affected with IRDs. The Open Access Genetic Testing Program, allows for any eye care professional in the U.S. to order the no-cost test along with a no-cost genetic counseling session for their IRD patients. Neither membership to My Retina Tracker Registry, nor clinician pre-approval, is needed to participate in the Open Access Genetic Testing Program and receive free testing and genetic counseling.

If a person who is tested chooses to join My Retina Tracker Registry, their data is automatically uploaded into their profile from the genetic testing laboratory.

Current sponsors of the new My Retina Tracker Registry include: The George Gund Foundation, Eloxx Pharmaceuticals, Sofia Sees Hope, AGTC and MeiraGTx. Sponsors of the Open Access Genetic Testing Program include: ProQR, Blueprint Genetics, InformedDNA, Sophia Sees Hope, and The George Gund Foundation.

About the Foundation Fighting BlindnessEstablished in 1971, the Foundation Fighting Blindness is the world's leading private funding source for retinal degenerative disease research. The Foundation has raised more than $760 million toward its mission of accelerating research for preventing, treating, and curing blindness caused by the entire spectrum of retinal degenerative diseases including: retinitis pigmentosa, age-related macular degeneration, Usher syndrome, and Stargardt disease. VisitFightingBlindness.orgfor more information.

Media Contact:Chris AdamsVice President, Marketing & Communicationscadams@fightingblindness.org410-423-0585

See the article here:
Foundation Fighting Blindness Launches Upgraded My Retina Tracker Registry for People with Inherited Retinal Diseases (IRDs) - Herald-Mail Media

In the season premiere of actressCourteney Coxs Facebook Watch Series Nine Months WithCourteney Cox, she opens up about her experience discovering she had aMTHFR gene mutation. Not only does this mutation make pregnancy difficult, but it also increases risk of types of cancer which is why genetic testing is crucial for everyone.

In her Facebook Watch stream, Cox, 55, revealed that she had suffered miscarriages in the past and four years ago discovered that it was due toMTHFR gene mutation. According to a study from theNational Center for Biotechnology Information (NCBI), this gene mutation also increases the risk of breast cancer as well as ovarian cancer. Additionally, Coxs father, Richard Lewis Cox, passed away after battling cancer in 2001.

Related:Sadness Is Not Always A Bad Thing Coping After Losing A Parent To Cancer

About four years ago, I found out I have something called a MTHFR gene mutation, which dictates how my body methylates, Cox explained in the video. I suffered miscarriages, my dad died of a really rare cancer, and depression runs in my family, which made my doctor think I should get this gene checked out. I discovered that I have the worst version of the mutation and my body doesnt methylate the way its supposed to.

For many people, genetic testing is a crucial step in understanding whether youre more or less at risk for a cancer diagnosis. Some specific gene mutations are directly linked to types of cancers, and by going through genetic testing, doctors will be able to identify these mutations in people. This is especially the case when it comes to ovarian cancer, which is linked toBRCA-1 and BRCA-2 gene defects.

Dr. Kellie Schneider explains why genetic testing is important to detect ovarian cancer

Genetic testing is important for several different reasons,Dr.Kellie Schneider, a gynecologic oncologist at Novant Health in Charlotte, North Carolina, tells SurvivorNet. Ovarian cancer is a relatively rare cancer so when we see it in a patient we worry theres something that put them genetically at risk for that cancer.We would want to know for their sake and their familys sake if we need to be screening for any additional cancers once they are in remission from their ovarian cancer.

Related: Ovarian Cancer: Understanding the Different Categories of Genetic Testing- What You Got From Your Parents & Whats Changed Since You Were Born

Genetic testing cannot only help a possible patient, but also their family members. Breast cancer survivor Amy Armstrong talked to SurvivorNet about why she got genetically tested for stomach cancer, which runs in her family.

[My mom] uncovered that she had a very rare stomach cancer gene called CDH1, Amy said. If you have this gene, not only is it incredibly rare, but youre also confronted [with] making a pretty big decision to avoid getting stomach cancer. You have to have a prophylactic gastrectomy. When my mom found out that she had the gene, it had a domino effect for not only her siblings to be tested for the gene, but also her children and 3 out of 4 of us, my siblings, tested positive for the gene.

According to Armstrong, CDH1 is a dominant gene so theres a 50/50 chance of passing it on to a child. In order to avoid passing this gene to her family, she underwent a prophylactic gastrectomy (stomach removal) to reduce her chance of getting cancer.

Breast cancer survivor Amy Armstrong shares why she went through genetic testing

Learn more about SurvivorNet's rigorous medical review process.

In the season premiere of actressCourteney Coxs Facebook Watch Series Nine Months WithCourteney Cox, she opens up about her experience discovering she had aMTHFR gene mutation. Not only does this mutation make pregnancy difficult, but it also increases risk of types of cancer which is why genetic testing is crucial for everyone.

In her Facebook Watch stream, Cox, 55, revealed that she had suffered miscarriages in the past and four years ago discovered that it was due toMTHFR gene mutation. According to a study from theNational Center for Biotechnology Information (NCBI), this gene mutation also increases the risk of breast cancer as well as ovarian cancer. Additionally, Coxs father, Richard Lewis Cox, passed away after battling cancer in 2001.

About four years ago, I found out I have something called a MTHFR gene mutation, which dictates how my body methylates, Cox explained in the video. I suffered miscarriages, my dad died of a really rare cancer, and depression runs in my family, which made my doctor think I should get this gene checked out. I discovered that I have the worst version of the mutation and my body doesnt methylate the way its supposed to.

For many people, genetic testing is a crucial step in understanding whether youre more or less at risk for a cancer diagnosis. Some specific gene mutations are directly linked to types of cancers, and by going through genetic testing, doctors will be able to identify these mutations in people. This is especially the case when it comes to ovarian cancer, which is linked toBRCA-1 and BRCA-2 gene defects.

Dr. Kellie Schneider explains why genetic testing is important to detect ovarian cancer

Genetic testing is important for several different reasons,Dr.Kellie Schneider, a gynecologic oncologist at Novant Health in Charlotte, North Carolina, tells SurvivorNet. Ovarian cancer is a relatively rare cancer so when we see it in a patient we worry theres something that put them genetically at risk for that cancer.We would want to know for their sake and their familys sake if we need to be screening for any additional cancers once they are in remission from their ovarian cancer.

Related: Ovarian Cancer: Understanding the Different Categories of Genetic Testing- What You Got From Your Parents & Whats Changed Since You Were Born

Genetic testing cannot only help a possible patient, but also their family members. Breast cancer survivor Amy Armstrong talked to SurvivorNet about why she got genetically tested for stomach cancer, which runs in her family.

[My mom] uncovered that she had a very rare stomach cancer gene called CDH1, Amy said. If you have this gene, not only is it incredibly rare, but youre also confronted [with] making a pretty big decision to avoid getting stomach cancer. You have to have a prophylactic gastrectomy. When my mom found out that she had the gene, it had a domino effect for not only her siblings to be tested for the gene, but also her children and 3 out of 4 of us, my siblings, tested positive for the gene.

According to Armstrong, CDH1 is a dominant gene so theres a 50/50 chance of passing it on to a child. In order to avoid passing this gene to her family, she underwent a prophylactic gastrectomy (stomach removal) to reduce her chance of getting cancer.

Breast cancer survivor Amy Armstrong shares why she went through genetic testing

Learn more about SurvivorNet's rigorous medical review process.

Here is the original post:
Actress Courteney Cox Says MTHFR Gene Mutation Made Pregnancy Difficult The Importance Of Genetic Testing To Detect Cancer Risk - SurvivorNet

A recent market intelligence study on the Genetic Testing Devices market2020incorporates proprietary techniques and assessment tools to screen the Genetic Testing Devices market for the forecast period, 2020-2026. Additionally, valuable insights pertaining to the market size, share and growth rate of Genetic Testing Devices market offers a greater chance of success for all business owners, products, and new technology.

Major Genetic Testing Devices market players covered by this research report are:

Myriad GeneticsCepheidLuminexSeegeneBioRad LaboratoriesWaferGen BiosystemsIntegraGenBioMerieuxInterpace DiagnosticsQiagenElitechElitechAbbott LaboratoriesBiocartisPerkinElmerRoche DiagnosticsEKF DiagnosticsQuest Diagnostics

Request for Sample Report @ https://www.reportspedia.com/report/life-sciences/global-genetic-testing-devices-market-report-2019,-competitive-landscape,-trends-and-opportunities/28940 #request_sample

Incorporated with Info-graphics, charts, tables and figures, this research report Genetic Testing Devices Market Size, Type Analysis, Application Analysis, End-Use Industry Analysis, Regional Outlook, Competitive Strategies And Forecasts, 2020- 2026is based on a wide-ranging research of the entire Global market and covering all its sub-segments through comprehensively thorough classifications. Insightful analysis and valuation are created from superior primary and secondary information sources with data and information derived from industry specialists across the value chain. The report provides historical market data for 2015-2019, base year estimates for 2020, and forecasts from 2020 to 2026.

Research Methodology:

The research report provides trustworthy primary and secondary research. It also depends on the most recent analysis techniques to organize extremely detailed and accurate research studies such as this Genetic Testing Devices Market. It uses data triangulation, top-down and bottom-up approaches, and advanced Genetic Testing Devices Market research processes to come out with comprehensive and industry-best market research reports.

Classification by Type is as follows:

Type 1Type 2Type 3

Classification by Application is as follows:

Application 1Application 2Application 3

Inquire Here For More Details Or Custom Content @ https://www.reportspedia.com/report/life-sciences/global-genetic-testing-devices-market-report-2019,-competitive-landscape,-trends-and-opportunities/28940 #inquiry_before_buying

Genetic Testing Devices Market 2020 Dynamics:

Drivers:(Developing regions and growing markets)

Boundaries:(Regional, Key Player facing Issues, Future Barriers for growth)

Opportunities:(Regional, Growth Rate, Competitive, Consumption)

Regional Segmentation:

TOC of Genetic Testing Devices Market 2020 Report Includes:

View Report TOC In detail @ https://www.reportspedia.com/report/life-sciences/global-genetic-testing-devices-market-report-2019,-competitive-landscape,-trends-and-opportunities/28940 #table_of_contents

Read this article:
Global Genetic Testing Devices Market Outlook, Opportunities, Key Players, Growth, Competitive Landscape, Trends and Forecast by 2026 - Cole of Duty

BIRMINGHAM, Ala. - Is personalized medicine cost-effective? University of Alabama at Birmingham researcher Nita Limdi, Pharm.D., Ph.D., and colleagues across the United States have answered that question for one medical treatment.

Patients experiencing a heart attack -- known as a myocardial infarction or an acute coronary syndrome -- have sharply diminished blood flow in coronary arteries, with a high risk of heart failure or death. Coronary angioplasty, a procedure to open narrowed or blocked arteries in the heart, and percutaneous coronary intervention, known as PCI or stenting, can restore blood flow to minimize damage to the heart. These procedures reduce the risk of subsequent major adverse cardiovascular events, or MACE, which include heart attacks, strokes or death.

But then, a treatment decision has to be made.

After stenting, all patients are treated with two antiplatelet agents for up to one year. Which combination of antiplatelets is best? The answer comes through pharmacogenomics, says Limdi, a professor in the UAB Department of Neurology and associate director of UAB's Hugh Kaul Precision Medicine Institute.

Pharmacogenomics combines pharmacology, the study of drug action, with genetics, the study of gene function, to choose the best medication according to each patient's personal genetic makeup. This is also called precision medicine -- tailored medical treatment for each individual patient.

The most commonly used antiplatelet combination after PCI is aspirin and clopidogrel, which is trademarked as Plavix. Clopidogrel is converted to its active form by an enzyme called CYP2C19. However, patients respond to clopidogrel differently based on their genetic makeup.

More than 30 percent of people have loss-of-function variants in the CYP2C19 gene that decrease the effectiveness of clopidogrel. The FDA warns that these patients may not get the full benefit of clopidogrel, which would increase the risk of MACE. So the FDA advises doctors to consider a different treatment such as prasugrel or ticagrelor, trademarked as Effient and Brillinta, to replace clopidogrel.

While most patients undergoing PCI receive clopidogrel without receiving any CYP2C19 loss-of-function testing, academic institutions like UAB that offer precision medicine use pharmacogenomics to guide the selection of medication dosing.

In 2018, Limdi and other investigators across nine United States universities -- all members of the Implementing Genomics in Practice consortium, or IGNITE -- showed that patients with loss-of-function variants who were treated with clopidogrel had elevated risks. There was a twofold increase in MACE risk for PCI patients, and a threefold increase in MACE risk among patients with acute coronary syndrome who received PCI, as compared to patients prescribed with prasugrel or ticagrelor instead of clopidogrel. Prasugrel and ticagrelor are not influenced by the loss-of-function variant and can substitute for clopidogrel, but they are much more costly and bring a higher risk of bleeding.

The IGNITE group then leveraged this real-world data to conduct an economic analysis to determine the best drug treatment for these heart disease patients.

A study led by Limdi and colleagues, published in the Pharmacogenomics Journal, examines the cost-effectiveness of genotype-guided antiplatelet therapy for acute coronary syndrome patients with PCI. This cost-effectiveness study is the first to use real-world clinical data; many cost-effectiveness studies use clinical trial data, which tends to exclude the sicker patients normally seen in clinical practice.

The study compared three main strategies: 1) treating all patients with clopidogrel, 2) treating all patients with ticagrelor, or 3) genotyping all patients and using ticagrelor in those with loss-of-function variants.

"We showed that tailoring antiplatelet selection based on genotype is a cost-effective strategy," Limdi said. "Support is now growing to change the clinical guidelines, which currently do not recommend genotyping in all cases. Evidence like this is needed to advance the field of precision medicine."

Costs, QALYs and ICERs

In the analysis, Limdi and colleagues considered differences in event rates for heart attacks and stent thrombosis in patients receiving clopidogrel versus ticagrelor versus genotype-guided therapy, during the one-year period following stenting. They also included medical costs from those events that are borne by the payer, such as admissions, procedures, medications, clinical visits and genetic testing. The analysis considered variations in event rates and medication costs over time to ensure that the results held under different scenarios.

The study uses an economic measure -- the QALY, which stands for the quality-adjusted life year.

"First, we looked at which strategy provided the highest QALY," Limdi said. "The QALY is the gold standard for measuring benefit of an intervention -- in our case, genotype-guided treatment compared to treatment without genotyping. Universal ticagrelor and genotype-guided antiplatelet therapy had higher QALYs than universal clopidogrel -- so those are the best for the patient."

But health care resources are not infinite. So, Limdi and colleagues then evaluated whether those interventions that have higher QALYs were also reasonable from a cost perspective. This analysis considered the willingness to pay. What would a payor or a patient pay for the highest QALY?

"In our case, the payor would recognize that ticagrelor is more expensive than clopidogrel -- $360 per month vs. $10 per month -- and there is a $100 cost for each genetic test," Limdi said. "So, from the payor perspective, the more effective strategy (one with a higher QALY) -- if more expensive (higher cost) -- would have to lower the risks of bad outcomes like heart attacks and strokes for the gains in QALY that are at, or below, the willingness-to-pay threshold."

A calculation called incremental cost-effectiveness ratios, or ICERs, assesses the incremental cost of the benefit (improvement in QALY). In the United States, a treatment is considered cost-effective if its associated ICER is at or below the willingness-to-pay threshold of $100,000 per QALY.

"In our assessment, the two strategies with the highest QALY had very different ICERs," Limdi said. "The genotype-guided strategy was cost-effective at $42,365 per QALY. Universal ticagrelor was not; it had an ICER of $227,044 per QALY."

The researchers also looked at some secondary strategies for a real-world reason. A number of clinicians now prescribe ticagrelor or prasugrel for the first 30 days after PCI, which is considered a period of greater risk, and then switch their patients to the less expensive drug clopidogrel.

The secondary analysis allowed Limdi and colleagues to explore the cost-effectiveness of giving all patients ticagrelor for 30 days, and then switching them to clopidogrel, without genetic testing, versus switching the patients based on genotype. Both strategies were better -- in terms of QALYs -- than a universal switch to clopidogrel at 30 days. However, neither of the two appeared to be cost-effective. Because these secondary strategies used estimated parameters, "the findings should only be considered as hypothesis-generating," Limdi said.

Read more from the original source:
Precision medicine guides choice of better drug therapy in severe heart disease - Science Codex

You cant accuse a monitor lizard of being a picky eater.

The carnivorous, fork-tongued reptiles feed on insects, spiders, bird eggs, mollusks, crabs, fish, amphibians and rodents dead or alive. Deer represent a large portion of the diets of the Komodo dragon, the largest monitor lizard species, which is native to eastern Indonesia.

Theyll feed at garbage piles and eat chicken bones. Whatevers available, said Fred Kraus, an evolutionary biologist at the University of Michigan. They probably would take puppies too, if they get them.

Monitor lizards have been found living on the most far-flung islands of Micronesia in the Pacific Ocean. For decades, people assumed humans dropped off these unfussy carnivores, turning them into especially threatening ecological invaders. But a study published Wednesday in Royal Society Open Science refutes this presumption, demonstrating that the monitor lizards of Palau, the Western Caroline Islands and the Mariana Islands are previously undescribed species native to those islands.

The team of scientists argues that the lizards likely rode ocean currents up to 1,500 miles in some cases, from Indonesia northeastward, where they naturally colonized these Pacific islands hundreds of thousands of years ago.

Some of those islands are so remote. Its pretty difficult to explain how they got there, said Valter Weijola, a biologist at Finlands University of Turku and lead author of the study. But his teams research shows they made this ocean crossing without help from humans. And since their disembarkment, theyve evolved into two distinct species.

Researchers examined more than 50 Micronesian monitor lizard specimens from museums around the world. First, they compared physical characteristics, measuring and noting details like body proportions, scale pattern and tongue color.

Then they ran molecular tests on tissue samples. DNA sequencing and analysis revealed two Micronesian species were genetically distinct from other known monitor lizards in the Asia-Pacific region. It also suggested each evolved in geographic and genetic isolation long before any humans arrived in Micronesia.

Used this way, DNA analysis can be a bit like looking at an ecological question through a microscope and a telescope simultaneously.

It takes you back in time and allows you to see things in greater detail, said Julie Lockwood, a Rutgers University ecologist and invasive species biologist who was not involved in the study.

That the islands included in the study have never been in contact with any continental landmass, nor with each other, indicates the lizards must have arrived overseas, perhaps on a raft of vegetation.

Theyre predisposed to being swept out to sea, Dr. Kraus said. They can survive a good while, riding that current.

It is possible that humans, particularly German and Japanese colonialists, introduced monitor lizards to some Micronesian islands during the early 20th century. But the study proves at least some of the islands monitor lizards got there before humans.

Because the lizards have been presumed to be invasive predators, local officials and inhabitants of these Micronesian islands have tried to curb or eradicate these populations.

Poisonous cane toads, for example, were brought to Kayangel Atoll in Palau to reduce monitor lizards predation on livestock. In the early 2010s, bounty programs in Angaur State, Palau, culled hundreds. And on Cocos Island off Guams coast, monitor lizard populations have been controlled to protect an endangered native bird. More plans are underway, according to the paper, to eradicate monitor lizards from Losiep Island in the Caroline Islands.

Whether a species is invasive or not reshapes conversations around conservation, Dr. Lockwood said. In a similar scenario in 2012, genetic testing revealed that red foxes preying on threatened shorebirds in the southeastern United States had arrived through the expansion of a natural Canadian range and not from an overseas translocation, as previously believed.

You may still have a reason to cull a predator population. But you cant use their native or nonnative status as justification, she said. Its possible well uncover more of these.

Researchers hope the revelation that monitor lizard species are natives could shift eradication efforts toward the islands other known invasives, such as brown tree snakes, feral pigs and nonnative deer, cats and rats.

Follow this link:
These Large Carnivorous Lizards Are Right Where They Belong - The New York Times

The Global Predictive Genetic Testing Market research report covers the size (value, production and consumption), splits the breakdown (data status 2015-2019 and forecast to 2027), by manufacturers, region, type and application. All the information in the research report is collected through primary and secondary research. Primary research collected by using various methods such as interviews, surveys and observation of analysts and secondary research grabbed by using well known paid sources, trade journals, and industry databases. The Predictive Genetic Testing Market report also utilizes qualitative and quantitative methods for analyzing data gathering from various industry analysts and market players.

Major Key Players for Global Predictive Genetic Testing Market. The report focuses on global major leading industry players of Predictive Genetic Testing market such as: Key players profiled in the report include: 23,Me Inc., Abbott, Ambry Genetics, BGI, Biocartis Group NV, Bio-Helix Co. Ltd., bioMerieux SA, Blueprint Genetics, Cepheid, Counsyl Inc., deCODE Genetics, GeneDx, Genomic Health Inc., Genomictree Inc., HTG Molecular Diagnostics Inc., Illumina Inc., IntegraGen, Invitae Corporation, LabCorp

Available Sample Report in PDF Version along with Graphs and Figures@ https://proficientmarket.com/sample/1198

Global Predictive Genetic Testing market report is divided into different segments such as product type Predictive Testing, Consumer Genomics, Wellness Genomics and applications types Breast and Ovarian Cancer, Cardiovascular screening, Diabetic Screening and Monitoring, Colon Cancer, Other, and report covers the various geographical regions such as North America, Asia-Pacific, Europe, Africa, South America, and other regions. Also, various countries included are Canada, U.K., France, the U.S., Russia, China, India, and Germany and so on.

On the basis of the market shares, revenue, and other important factors all the segments are included in the Predictive Genetic Testing market report. And the reports various segments are adding the growth in the global Predictive Genetic Testing market. The report also provides information on the current key trends according to the segment analysis. With the help of all this detailed information existing and new market players getting the exact promising regions of the global Predictive Genetic Testing market. The research report also offers an independent analysis of the segments according to the market opportunity.

Grab Best Discount on Predictive Genetic Testing Market Research Report [Single User | Enterprise Users] @ https://proficientmarket.com/buying-request/1198

According to the current market situation, Predictive Genetic Testing market manufacturers understand, collect and auspicious convey appraisal on effect of COVID-19 fiasco on numerous companies and their customers to help them in taking fantastic business choices. This research report also analyzes the market status, market share, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porters Five Forces Analysis.

Global Predictive Genetic Testing Market Segments and Sub-segments:

Read the full press release and latest news of this report, here: https://proficientmarket.com/press-release/1203/global-predictive-genetic-testing-market

There are 13 Chapters to display the Global Predictive Genetic Testing market:

Chapter 1: Market Overview, Drivers, Restraints and Opportunities, Segmentation overviewChapter 2: Market Competition by ManufacturersChapter 3: Production by RegionsChapter 4: Consumption by RegionsChapter 5: Production, By Types, Revenue and Market share by TypesChapter 6: Consumption, By Applications, Market share (%) and Growth Rate by ApplicationsChapter 7: Complete profiling and analysis of ManufacturersChapter 8: Manufacturing cost analysis, Raw materials analysis, Region-wise manufacturing expensesChapter 9: Industrial Chain, Sourcing Strategy and Downstream BuyersChapter 10: Marketing Strategy Analysis, Distributors/TradersChapter 11: Market Effect Factors AnalysisChapter 12: Market ForecastChapter 13: Predictive Genetic Testing Research Findings and Conclusion, Appendix, methodology and data source.

Browse the complete report @ https://proficientmarket.com/report/1198/global-predictive-genetic-testing-market

Pivotal Findings of the Global Predictive Genetic Testing Market Report:

About Us:Proficient Market is the leading research company offering both tactical and strategic support to all our customers. Customer satisfaction is our goal and that is why, we have a team of skilled and experienced specialists with the ability to do data mining, information management, and revenue enhancement solutions to ensure that our clients make informed decisions when coming to investing in the market. Our happiness is when we help our clients grow their business, strengthen the brands and educate their members or consumers through the ever-new fun research methods developed by our team.

Contact Us:Proficient Market1st Floor, Harikrishna Building,Samarth Nagar, New Sanghvi,Pune- 411027 IndiaTel: +91-8149441100 |+17738002974Email: sales@proficientmarket.comWeb: proficientmarket.com

See the original post:
Global Predictive Genetic Testing Market Report 2020- Covering Impact of COVID-19, Financial Information, Developments, SWOT Analysis by Global Top...

On May 8, the Food and Drug Administration (FDA) granted accelerated approval of Retevmo (selpercatinib), the first RET inhibitor, for people with non-small-cell lung cancer (NSCLC) and two types of thyroid cancer with specific genetic mutations.

Innovations in gene-specific therapies continue to advance the practice of medicine at a rapid pace and offer options to patients who previously had few, Richard Pazdur, MD, director of the FDAs Oncology Center of Excellence, said in a press release.

Retevmo, from Eli Lilly and companywhich obtained the drug, then known as LOXO-292, when it acquired Loxo Oncology last yearis a selective inhibitor of a receptor tyrosine kinase known as RET. This enzyme plays a role in cell proliferation, and mutations or fusions in the RET gene can drive cancer development. RET alterations are rare overall, occurring in less that 1% of all cancers and 2% of NSCLC, but they are more frequent in certain cancer types.

Drugs that work against cancers with a specific genetic alteration anywhere in the body are known as pancancer, or site-agnostic, therapies. Retevmo, however, was approved for specific cancer types. It is indicated for adults with metastatic RET fusion-positive NSCLC and for adults and adolescents (age 12 and up) with advanced or metastatic RET fusion-positive thyroid cancer or advanced or metastatic RET-mutant medullary thyroid cancer. Medullary thyroid cancer, which involves a specific type of cell, is uncommonaccounting for only 4% of all thyroid cancersbut it frequently has RET mutations.

Retevmo can be used regardless of prior treatment history, both by those who have tried prior systemic medications and those starting treatment for the first time.

The accelerated approval was based on promising findings from the Phase I/II LIBRETTO-001 trial. Study results were previously presented at the 2018 American Society of Clinical Oncology annual meeting,the 2019 World Conference on Lung Cancerand the 2019 European Society for Medical Oncology Congress.

LIBRETTO-001 enrolled people with NSCLC, thyroid cancer and a variety of other solid tumors with RET mutations or fusions. Both previously treated patients and those starting systemic treatment for the first time were eligible. Everyone was treated with Retevmo, taken as a pill twice daily; there was no placebo group.

Retevmo led to an overall response ratemeaning complete or partial tumor shrinkagein 64% of the 105 previously treated people with NSCLC, rising to 85% for the 39 patients new to treatment. The mediation duration of response was 17.5 months for the treatment-experienced group, and was not reached in the newly treated group because a majority were still responding.

When he presented preliminary study findings last year, Alexander Drilon, MD, of Memorial Sloan Kettering Cancer Center in New York City, noted that Retevmo appeared particularly active against cancer that had spread to the brain. Ten of the 11 people with brain metastasis (91%) experienced shrinkage of cancer in the brain, including 18% with complete remission.

In the clinical trial, we observed that the majority of metastatic lung cancer patients experienced clinically meaningful responses when treated with selpercatinib, including responses in difficult-to-treat brain metastases, Drilon said in a Lilly press release. The approval of selpercatinib marks an important milestone in the treatment of NSCLC, makingRET-driven cancers now specifically targetable in the same manner as cancers with activating EGFR and ALK alterations, across all lines of therapy.

Looking at the participants with thyroid cancer, the overall response rate was 69% for the 55 treatment-experienced patients and 73% for the 88 previously untreated people with RET-mutant medullary thyroid tumors. Here, the duration of response was 22.0 months for the previously untreated group and not reached for the treatment-experienced group. In the smaller subset of 19 previously treated and eight newly treated people with RET fusion-positive thyroid cancer, the overall response rates were 79% and 100%, respectively. Response duration was 18.4 months in the former group and not reached in the latter group.

RETalterations account for the majority of medullary thyroid cancers and a meaningful percentage of other thyroid cancers, saidLori Wirth, MD, of Massachusetts General Hospital Cancer Center. For patients living with these cancers, the approval of selpercatinib means they now have a treatment option that selectively and potently inhibitsRET.

Treatment with Retevmo was generally safe and well tolerated, with just 5% of participants stopping treatment because of adverse events. The most common adverse reactions include diarrhea, constipation, dry mouth, fatigue, swelling, rash, high blood pressure, elevated ALT and AST liver enzymes, elevated glucose, cholesterol and creatinine, and various other laboratory test abnormalities.

The product label for Retevmo includes warnings about several potential serious side effects: liver toxicity, severe high blood pressure, bleeding, heart rhythm abnormalities, hypersensitivity reactions and slow wound healing. Retevmo can cause fetal harm if used during pregnancy.

A Lilly spokesperson told FiercePharma that Retevmo would be available from specialty pharmacies within a week at a list price of about $20,600 for a 30-day supply.

Drugs that receive accelerated approval based on response rates in early studies are expected to undergo further testing in larger randomized trials to confirm clinical benefits such as improved survival, and the FDAcan rescind approval if they dont measure up. Two Phase III trials, Libretto-431 for NSCLC (ClinicalTrials.gov number NCT04194944) and Libretto-531 for medullary thyroid cancer (ClinicalTrials.gov number NCT04211337), are currently underway.

Another investigational RET inhibitor, Blueprint Medicines pralsetinib (formerly known as BLU-667) has also demonstrated good activity in an early study, with overall response rates of 60% for NSCLC patients who used prior platinum-based chemotherapy and 71% for previously untreated people.

The availability of RET inhibitors underscores the need for genetic testing to determine which patients have gene mutations or fusions that could make them eligible for these new targeted therapies. Next-generation sequencing of a tumor tissue biopsy sample or liquid biopsy using a blood sample can reveal multiple actionable genetic alterations. However, there is currently no FDA-approved companion test specifically for RET alterations.

Increasingly, through the use of comprehensive biomarker testing, patients with metastatic cancer have an opportunity to receive a treatment tailored to the specific genomic nature of their tumor, Andrea Ferris, president and chief executive officer of LUNGevity, said in the Lilly press release. We urge patients to ask their doctors about broad biomarker tests that includeRETalterations.

Click here for full prescribing information for Retevmo.

Click here to learn more about lung cancer.

Click here to learn more about thyroid cancer.

See the rest here:
FDA Approves RET Inhibitor Retevmo for Lung and Thyroid Cancer - Cancer Health Treatment News

COLLEGE STATION, Texas SeniorsRaenaEldridge and Benjamin Walker of the Texas A&M womens and mens swimming & diving programs have been nominated for the H. Boyd McWhorter Scholar-Athlete Post-Graduate Scholarship.The H. Boyd McWhorter Scholar-Athlete Post-Graduate Scholarship has been presented by the Southeastern Conference since 1986 to the league's top male and female scholar-athletes. The SEC will name the 2020 recipients, chosen by a committee of Faculty Athletics Representatives from the 14 SEC institutions, in late May.Eldridge recently earned her degrees from A&M, majoring in animal science and genetics. The Rockwall, Texas, native has garnered CSCAA Scholar All-America honors every year of her career, while also being named to the SEC Academic Honor Roll each season. For the second straight year, Eldridge was awarded Bill Erwin Scholar-Athlete of the Year honors, recognizing the top male and female student-athletes at Texas A&M who balance athletics and academics while maintaining above a 3.25 GPA, at the recent Building Champions Awards. Eldridge has served as a project leader for the Aggie Research Scholars Program and as a Student Technician of the Genetics Research Lab. Eldridge captained the womens squad as a junior and senior, and earned CSCAA All-America honors twice, while helping her team to three straight SEC Championships.Walker recently earned his degree in accounting from the Mays Business School. He was a two-timeCSCAAScholar All-American and has earned a spot on the SEC Academic Honor Roll in each year of his career. Walker, who hails from The Woodlands, Texas, made A&M history as a junior when he became the program's first individual swimming SEC Champion, winning the 200 Breast. He again claimed gold in the event with a school-record time of 1:51.92, while helping both medley relay teams to podium finishes at the 2020 SEC Championships. The three-timeCSCAAAll-American also holds the Texas A&M all-time school record in the 100 Breast, and was part of the record-holding 200 and 400 medley relay teams, both setting a new program mark at this year's SEC Championships. A team captain in his final season, Walker helped A&M move up the dual meet rankings, rising as high as fourth for the team's highest ranking since the 2001 season.The SEC provides the league's male and female McWhorter Scholar-Athlete of the Year Post-Graduate Scholarship recipients with a $20,000 post-graduate scholarship. The 26 remaining male and female finalists for the award will also receive a $10,000 post-graduate scholarship.

Follow this link:
Eldridge, Walker Named McWhorter Scholar-Athlete of the Year Nominees - KAGSTV.com

- Data to be Presented Underscore Progress in Addressing Unmet Needs Across Multiple Tumor Types -

- Additional Results for Recently FDA-Approved TUKYSA(tucatinib) to be Featured in Oral Presentation -

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the presentation of new data from its expanding pipeline of marketed and investigational therapies in the virtual scientific program of the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place on May 29-31. Thirteen abstracts including an oral presentation of new data from patients with brain metastases who were part of the pivotal HER2CLIMB trial of TUKYSA (tucatinib) in patients with previously treated HER2-positive metastatic breast cancer will highlight the company’s continued progress in advancing research in cancers that have a significant unmet need.

Over the past six months, we have been able to deliver on our promise of bringing important new medicines to certain patients with HER2-positive metastatic breast cancer and metastatic urothelial cancer through two U.S. FDA approvals,” said Clay Siegall, Ph.D., Chief Executive Officer at Seattle Genetics. We look forward to sharing data in the ASCO virtual scientific program that reinforce our ability to rapidly advance novel targeted agents across multiple tumor types.”

An Expanding Portfolio of Marketed Therapies

Key data presentations will showcase progress for certain patients with HER2-positive metastatic breast cancer and metastatic urothelial cancer as well as for patients with classical Hodgkin lymphoma (HL). Highlights include:

TUKYSA Update in Patients with Brain Metastases

Results for TUKYSA in combination with trastuzumab and capecitabine in patients with brain metastases from the HER2CLIMB pivotal trial of previously treated patients with HER2-positive metastatic breast cancer will be featured in an oral session (Abstract #1005). Data will be presented from these exploratory analyses on findings from the TUKYSA arm of the study on reduction in the risk of death (OS), reduction in the risk of intracranial progression or death (CNS-PFS) and improvement of the intracranial confirmed objective response rate (ORR-IC) compared to trastuzumab and capecitabine. Data will be presented by Nancy U. Lin, Director of the Metastatic Breast Cancer Program in the Susan F. Smith Center for Women’s Cancers at Dana-Farber in Boston, MA, during an oral presentation available on demand at 8:00 a.m. ET on May 29, 2020. A separate analysis of adverse events (AE) from the same trial will be presented (Abstract #1043; poster presentation).

PADCEV (enfortumab vedotin-ejfv) in Combination and in Other Solid Tumors

Additional results and durability data from the phase 1b EV-103 trial of PADCEV plus pembrolizumab in first-line metastatic urothelial cancer will be presented (Abstract #5044), and a separate Trials-in-Progress poster will provide details about a new randomized cohort added to the EV-103 study, Cohort K, which is evaluating PADCEV as monotherapy or in combination with pembrolizumab (#TPS5092). Both presentations will be featured in the Genitourinary CancerKidney and Bladder session. Data from the Cohort K, along with other data from the EV-103 trial evaluating PADCEV combined with pembrolizumab as first-line therapy for cisplatin-ineligible patients, could potentially support registration under accelerated approval regulations in the United States.

Additionally, information about the phase 2 EV-202 trial, which is studying PADCEV in six different types of locally advanced and metastatic solid tumors (HR-positive/HER2-negative and triple-negative breast cancers, squamous and non-squamous non-small cell lung cancers, head and neck cancer and gastroesophageal cancers), will be discussed in a Trials-in-Progress poster during the Developmental Therapeutics Molecularly Targeted Agents and Tumor Biology Poster Session (Abstracts #TPS3647).

ADCETRIS® (brentuximab vedotin) Continues to Advance

Data to be presented on ADCETRIS will demonstrate the company’s progress in efforts to continue expanding clinical research on combination regimens and monotherapy in a variety of HL and peripheral T-cell lymphoma (PTCL) patient populations, including in both older and younger disease settings. A poster presentation will highlight the potential of ADCETRIS in combination with nivolumab or dacarbazine and as a monotherapy for previously untreated older HL patients who typically have poorer outcomes than younger patients due to comorbidities and toxicities related to standard first-line chemotherapy (Abstract #8032). The primary analysis from an ongoing clinical trial evaluating ADCETRIS plus nivolumab in children, adolescents and young adults with standard-risk relapsed or refractory classical HL will also be presented (Abstract #8013; poster discussion). Lastly, two Trials-in-Progress poster presentations will highlight ongoing clinical trials evaluating ADCETRIS as a monotherapy in frontline older HL or CD30-expressing PTCL patients and in a combination regimen in frontline advanced-stage HL patients (Abstracts #TPS8069 and #TPS8068).

A Strong, Diverse Pipeline of Investigational Therapies

An additional four Trials-in-Progress posters for investigational therapies will showcase the company’s continued clinical development of pipeline candidates in first-line cervical cancer (Abstract #TPS6095), metastatic breast cancer (Abstract #TPS1104), metastatic pancreatic ductal adenocarcinoma (PDAC) (Abstract #TPS4671) and other solid tumors (Abstract #TPS3652).

The abstracts published in advance of the ASCO meeting were made available today on the ASCO website. All data presentations will be available on-demand on May 29, 2020.

Details of Key Seattle Genetics Presentations at ASCO20 Virtual:

Abstract Title

Abstract #

Presentation Type

Presenter

ADCETRIS® (brentuximab vedotin)

Nivolumab and brentuximab vedotin (BV)-based, response‐adapted treatment in children, adolescents, and young adults (CAYA) with standard-risk relapsed/refractory classical Hodgkin lymphoma (R/R cHL): Primary analysis

8013

Poster discussion

P. Cole

Frontline Brentuximab Vedotin as Monotherapy or in Combination for Older Hodgkin Lymphoma Patients

8032

Poster presentation

C. Yasenchak

PADCEV (enfortumab vedotin-ejfv)

Study EV-103: Durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma

5044

Poster presentation

J. Rosenberg

TUKYSA (tucatinib)

Tucatinib vs Placebo Added to Trastuzumab and Capecitabine for Patients with Previously Treated HER2+ Metastatic Breast Cancer with Brain Metastases (HER2CLIMB)

1005

Oral presentation

N. Lin

Management of adverse events in patients with HER2+ metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine (HER2CLIMB)

1043

Poster presentation

A. Okines

Trials-in-Progress

ADCETRIS® (brentuximab vedotin)

Frontline brentuximab vedotin in Hodgkin lymphoma and CD30-expressing peripheral T-cell lymphoma for older patients and those with comorbidities

TPS8069

Poster presentation

C. Yasenchak

Brentuximab Vedotin in Combination with Nivolumab, Doxorubucin, and Dacarbazine in Newly Diagnosed Patients with Advanced Stage Hodgkin Lymphoma

TPS8068

Poster presentation

J. Friedman

PADCEV (enfortumab vedotin-ejfv)

Study EV-103: New randomized cohort testing enfortumab vedotin as monotherapy or in combination with pembrolizumab for locally advanced or metastatic urothelial carcinoma

TPS5092

Poster presentation

N. Mar

EV-202: A Phase 2 Study of Enfortumab Vedotin in Patients With Select Previously Treated Locally Advanced or Metastatic Solid Tumors

TPS3647

Poster presentation

J. Bruce

Investigational Therapies

Phase 1b/2 trial of tisotumab vedotin (TV) ± bevacizumab (BEV), pembrolizumab (PEM), or carboplatin (CBP) in recurrent or metastatic cervical cancer (innovaTV 205/ENGOT-cx8/GOG-3024)

TPS6095

Poster presentation

I. Vergote

SGNLVA-001: A phase 1 open-label dose escalation and expansion study of SGN-LIV1A administered weekly in breast cancer

TPS1104

Poster presentation

H. Beckwith

SGN228-001: A phase 1 open-label dose escalation and expansion study of SGN-CD228A in select advanced solid tumors

TPS3652

Poster presentation

A. Patnik

Phase 1 study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients (pts) with metastatic pancreatic ductal adenocarcinoma (PDAC)

TPS4671

Poster presentation

A. Coveler

About ADCETRIS (brentuximab vedotin)

ADCETRIS is an antibody-drug conjugate (ADC) comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Seattle Genetics’ proprietary technology. The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-expressing tumor cells. Seattle Genetics and Takeda are jointly developing ADCETRIS.

About PADCEV (enfortumab vedotin-ejfv)

PADCEV is an antibody-drug conjugate (ADC) that is directed against Nectin-4, a protein located on the surface of cells and highly expressed in bladder cancer. Nonclinical data suggest the anticancer activity of PADCEV is due to its binding to Nectin-4 expressing cells followed by the internalization and release of the anti-tumor agent monomethyl auristatin E (MMAE) into the cell, which result in the cell not reproducing (cell cycle arrest) and in programmed cell death (apoptosis). PADCEV is co-developed by Seattle Genetics and Astellas.

About TUKYSA (tucatinib)

TUKYSA is an oral medicine that is a tyrosine kinase inhibitor of the HER2 protein. In vitro (in lab studies), TUKYSA inhibited phosphorylation of HER2 and HER3, resulting in inhibition of downstream MAPK and AKT signaling and cell growth (proliferation), and showed anti-tumor activity in HER2-expressing tumor cells. In vivo (in living organisms), TUKYSA inhibited the growth of HER2-expressing tumors. The combination of TUKYSA and the anti-HER2 antibody trastuzumab showed increased anti-tumor activity in vitro and in vivo compared to either medicine alone.

ADCETRIS (brentuximab vedotin) U.S. Important Safety Information

BOXED WARNING

PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML): JC virus infection resulting in PML and death can occur in ADCETRIS-treated patients.

Contraindication

ADCETRIS concomitant with bleomycin due to pulmonary toxicity (e.g., interstitial infiltration and/or inflammation).

Warnings and Precautions

Administer G-CSF primary prophylaxis beginning with Cycle 1 for patients who receive ADCETRIS in combination with chemotherapy for previously untreated Stage III/IV cHL or previously untreated PTCL.

Monitor complete blood counts prior to each ADCETRIS dose. Monitor more frequently for patients with Grade 3 or 4 neutropenia. Monitor patients for fever. If Grade 3 or 4 neutropenia develops, consider dose delays, reductions, discontinuation, or G-CSF prophylaxis with subsequent doses.

Most Common (20% in any study) Adverse Reactions

Peripheral neuropathy, fatigue, nausea, diarrhea, neutropenia, upper respiratory tract infection, pyrexia, constipation, vomiting, alopecia, decreased weight, abdominal pain, anemia, stomatitis, lymphopenia, and mucositis.

Drug Interactions

Concomitant use of strong CYP3A4 inhibitors or inducers has the potential to affect the exposure to monomethyl auristatin E (MMAE).

Use in Specific Populations

Moderate or severe hepatic impairment or severe renal impairment: MMAE exposure and adverse reactions are increased. Avoid use.

Follow this link:
Seattle Genetics Highlights Data from Expanding Oncology Portfolio During Virtual Scientific Program of the 2020 ASCO Annual Meeting - Stockhouse

Since the outbreak of the COVID-19 pandemic a few months ago, doctors and researchers have been wondering about the causes behind the disparate effects of the infection, whose spectrum ranges from the absolute absence of symptoms to extremely serious symptoms such as , for example, acute respiratory distress syndrome, which cause death on more than a few occasions. What explains such variability? Does the answer reside in our genes?

TLR receivers

Coronaviruses have raised such questions for more than 15 years. In a first study of the severe acute respiratory syndrome (SARS) outbreak in 2003, Ralph Baric and colleagues at the University of North Carolina at Chapel Hill found that inactivation of a gene caused by a mutation turned mice into highly sensitive to SARS-CoV, the disease-causing coronavirus. The gene in question, TICAM2, encodes a helper protein that is involved in the activation of a family of receptors, that of the toll-like receptors (TLR). These are involved in the mechanisms of innate immunity, which constitutes the first line of defense against pathogenic microbes.

Now the focus has shifted to SARS-CoV-2, the new coronavirus responsible for COVID-19, but TLRs have garnered interest again, this time following attempts to explain the marked prevalence of sex. male among people with a serious infection.

According to a national epidemiological study carried out in France and published on April 23, up to 73 percent of those admitted by COVID-19 in intensive care units in that country were men. Differences in habits and hormonal nature would partially explain this preponderance, but genes would have something to do with the situation as well. Unlike men, women have two X chromosomes, so they have twice as many copies of the TLR7 gene, an essential detector of viral activity that enhances the immune response capacity.

Blood groups

The genetics of blood groups also seems to provide clues to a persons risk of severe coronavirus infection. In late March, Peng George Wang of the Southern China University of Science and Technology released the results of a study by his team, not yet externally reviewed, comparing the distribution of blood groups in 2,173 COVID-19 patients treated at three hospitals in the cities of Wuhan and Shenzhen with that of other uninfected citizens in those areas. Blood group A would be associated with a higher risk of contracting the virus, in contrast to type O, which would confer more protection for reasons that are still unknown.

The SARS outbreak of the past decade offers lessons. ABO blood groups are based on two types of carbohydrates (or sugars) present on the surface of red blood cells. The first corresponds to type A and the second to type B. Each sugar molecule is synthesized by an enzyme whose gene is present in two forms (one is responsible for type A and the other is responsible for type B). A third encodes an inactive version of the enzyme: type O (from the German ohne, without). The person carrying the two active enzyme variants, A and B, has type AB blood.

Both carbohydrates, A and B, act as antigens, that is, they trigger the production of antibodies that recognize the antigens that the individual lacks, which is why precautions must be taken in blood transfusions. In the ABO system, type O blood is the richest in antibodies, since it contains both anti-A and anti-B antibodies, while type AB blood does not have any.

In 2008 Jacques Le Pendu of the University of Nantes and his collaborators investigated an in vitro model of SARS-CoV. They found that the anti-A antibody neutralizes the binding of the viruss protein S to the ACE2 receptor (angiotensin-converting enzyme), a necessary step for the infection of the cell to be consumed (as soon as to anti-B antibody, data not yet available).

ACE1 versus ACE2

Another protein very close to ACE2 involved in the control of blood pressure is the angiotensin converting enzyme type 1 (ACE1). The ACE1 gene of the latter is polymorphic, that is, there are several variants (or alleles) thereof, of which D is associated with a reduced expression of the related ACE2 gene. As a result, cells carrying the ACE1 D gene have fewer receptors that serve as a gateway for the SARS-CoV virus. The frequency of the ACE1 D variant is not the same in all countries, especially in Europe, which raises the question of whether the geographical distribution of this variant could not be interrelated with the prevalence of COVID-19. Would this reflect the epidemiology of infection on a global scale? The investigations of the team led by Marc De Buyzere, at the University of Ghent, point in that direction.

Using data from 25 countries (from Portugal to Estonia and from Turkey to Finland), Belgian researchers have calculated that 38 percent of the variability in the prevalence of the disease is explained by the frequency of the D allele of ACE1. Furthermore, a similar correlation is observed in mortality statistics. They also highlight that the D allele is rare in the population of two Asian countries that have been severely affected by SARS-CoV-2.

Another genetic component that could explain vulnerability to the new coronavirus is the genes that encode human leukocyte antigens (HLA), a set of proteins that prevent the immune system from attacking the body itself. These proteins constitute the main histocompatibility complex (MHC), which marks all the cells and tissues of their own and differentiates them from everything that is not. Reid Thompson and colleagues at the Oregon Health and Science University in Portland have discovered a link between certain HLA genes and the severity of COVID-19.

People with the HLA-B * 46: 01 variant appear to be especially vulnerable to SARS-CoV-2, as was previously demonstrated with SARS-CoV. In contrast, the HLA-B * 15: 03 variant would confer a certain degree of protection. Determining a persons HLA gene envelope, using quick and inexpensive analysis, would help better predict the severity of the infection and detect those in whom vaccination would be a priority, according to the researchers.

Major projects

To learn more about the genetic variants that influence SARS-CoV-2 infection, a multitude of projects are underway. In one of them, Andrea Ganna, from the University of Helsinki, has launched the COVID-19 Host Genetics Initiative, which aims to unite the efforts of the international community of geneticists working on this issue. For his part, Jean-Laurent Casanova, from the Parisian Necker Pediatric Hospital and Rockefeller University in New York, coordinates a similar project that seeks to discover the genetic variants that favor the most serious forms of COVID-19 in minors. 50 years.

There is no doubt that we are not equal to SARS-CoV-2, but if we discover what causes such differences, perhaps we can alleviate them.

Loc Mangin

Find here all the contents of Research and Science on the COVID-19 pandemic. You can also access articles published by Scientific American and other international editions through this web.

(function() {var _fbq = window._fbq || (window._fbq = []);if (!_fbq.loaded) {var fbds = document.createElement('script');fbds.async = true;fbds.src = "https://connect.facebook.net/en_US/fbds.js";var s = document.getElementsByTagName('script')[0];s.parentNode.insertBefore(fbds, s);_fbq.loaded = true;}})();window._fbq = window._fbq || [];

Go here to read the rest:
Is there a genetic predisposition to suffer from COVID-19? | Present - Explica

Global Milk Thistle Health Tonic Market Size, Status and Forecast 2020-2026

This report studies the Milk Thistle Health Tonic market with many aspects of the industry like the market size, market status, market trends and forecast, the report also provides brief information of the competitors and the specific growth opportunities with key market drivers. Find the complete Milk Thistle Health Tonic market analysis segmented by companies, region, type and applications in the report.

New vendors in the market are facing tough competition from established international vendors as they struggle with technological innovations, reliability and quality issues. The report will answer questions about the current market developments and the scope of competition, opportunity cost and more.

The major players covered in Milk Thistle Health Tonic Market: Health Genesis, Pure Encapsulations, Regis, Solgar, Aksuvital, BEC, NC, Life Extension, Swisse, HerbsofGold

The final report will add the analysis of the Impact of Covid-19 in this report Milk Thistle Health Tonic industry.

Get a Free Sample Copy @ https://www.reportsandmarkets.com/sample-request/impact-of-covid-19-outbreak-on-milk-thistle-health-tonic-global-market-research-report-2020

Global Milk Thistle Health Tonic Market: Competitive Landscape

This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and production by manufacturers during the forecast period of 2020 to 2026.

This report focuses on the global Milk Thistle Health Tonic status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Milk Thistle Health Tonic development in United States, Europe, China, Japan, Southeast Asia, India, and Central & South America.

The Milk Thistle Health Tonic market is a comprehensive report which offers a meticulous overview of the market share, size, trends, demand, product analysis, application analysis, regional outlook, competitive strategies, forecasts, and strategies impacting the Milk Thistle Health Tonic Industry. The report includes a detailed analysis of the market competitive landscape, with the help of detailed business profiles, SWOT analysis, project feasibility analysis, and several other details about the key companies operating in the market.

Segment by Type

Segment by Application

The study objectives of this report are:

Inquire More about This Report @ https://www.reportsandmarkets.com/enquiry/impact-of-covid-19-outbreak-on-milk-thistle-health-tonic-global-market-research-report-2020

The Milk Thistle Health Tonic market research report completely covers the vital statistics of the capacity, production, value, cost/profit, supply/demand import/export, further divided by company and country, and by application/type for best possible updated data representation in the figures, tables, pie chart, and graphs. These data representations provide predictive data regarding the future estimations for convincing market growth. The detailed and comprehensive knowledge about our publishers makes us out of the box in case of market analysis.

Key questions answered in this report

Table of Contents

Chapter 1: Global Milk Thistle Health Tonic Market Overview

Chapter 2: Milk Thistle Health Tonic Market Data Analysis

Chapter 3: Milk Thistle Health Tonic Technical Data Analysis

Chapter 4: Milk Thistle Health Tonic Government Policy and News

Chapter 5: Global Milk Thistle Health Tonic Market Manufacturing Process and Cost Structure

Chapter 6: Milk Thistle Health Tonic Productions Supply Sales Demand Market Status and Forecast

Chapter 7: Milk Thistle Health Tonic Key Manufacturers

Chapter 8: Up and Down Stream Industry Analysis

Chapter 9: Marketing Strategy -Milk Thistle Health Tonic Analysis

Chapter 10: Milk Thistle Health Tonic Development Trend Analysis

Chapter 11: Global Milk Thistle Health Tonic Market New Project Investment Feasibility Analysis

About Us:

Reports and Markets is not just another company in this domain but is a part of a veteran group called Algoro Research Consultants Pvt. Ltd. It offers premium progressive statistical surveying, market research reports, analysis & forecast data for a wide range of sectors both for the government and private agencies all across the world. The database of the company is updated on a daily basis. Our database contains a variety of industry verticals that include: Food Beverage, Automotive, Chemicals and Energy, IT & Telecom, Consumer, Healthcare, and many more. Each and every report goes through the appropriate research methodology, Checked from the professionals and analysts.

Contact Us:

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

More:
Milk Thistle Health Tonic (Impact of COVID-19) Market Growth, Overview with Detailed Analysis 2020-2026| Health Genesis, Pure Encapsulations, Regis,...

The union representing some 400 workers on the Terra Nova FPSOoil platform is sounding the alarm about a scenario that could see the vessel not produce any oil for the next two years.

"The members are very worried about their future, and the future of Newfoundland (and Labrador)," said Unifor Local 2121 president Dave Mercer.

Companies that supply the offshore are also feeling the pinch from an oil industry that has been thrown into crisis by a global pandemic.

"The impact directly is the loss of some supply ships that we supply. They're tied up or moved on somewhere else. We don't have that business or as much," said Gary Squires, manager at St. John's-based Campbell's Ship Supplies, which providessupplies to supply ships and drill rigs in the offshore.

Campbell's has a workforce of 25, and so far has been able to avoid any layoffs, said Squires.

His comments reflecta moodnow permeating an industry that represents some 30 per cent of the value of the province's gross domestic product, and uncertainty about the future of the Terra Nova FPSO is the latest dark cloud to cast a shadow over the offshore sector.

"Now it's time for the government to step up," said Mercer, whose union represents nearly 800 workers on the Terra Nova and Hibernia oil platform.

Workers on the Hebron and SeaRose FPSO platforms are not unionized.

Suncor, the majority owner and operator of Terra Nova, confirmed this week that it was unable to formalize a Plan B for a life extension overhaulof the aging floating, production, storage and offloading vessel, which has been producing oil on the Grand Banks since 2002.

As a result,the partnership that owns the vessel has decided to remove the Terra Nova from the offshore by this summer,and sail it to port at a location yet to be named, for an unknown duration.

"Obviously we're very concerned about the impacts to industry, the impacts to employment, the impacts to Newfoundlanders and Labradorians of the challenges that the industry is facing," said provincial Natural Resources Minister Siobhan Coady.

Coadyhas been in discussions with the operator, but said there's no indication yet how many jobs will be lost, or when the Terra Nova might return to the offshore and resume production, but she acknowledged it could very well be 2022.

Mercer said the union is also scrambling for information.

"It's all so fluid," he said.

Suncor released a statement Tuesday that said, "No decisions have been made to shut down production operations on Terra Nova until 2022."

But with so much uncertainty caused by the global pandemic, oil markets that are extremely volatile, and the immense planning that goes into a refit like the one proposed for the Terra Nova, insiders predict a lengthy shutdown for the vessel.

The Terra Nova was supposed to be at a dockyard in Spain by now, undergoing a half-billion-dollar life extension refit that would extend the oil field for 10 years, and allow the vessel to produce an additional 80 million barrels of oil.

But with Spain hit hard by the COVID-19 virus, those plans have been scuttled, and when Suncor was unable to come up an with an alternative plan, the decision was made to mothball the vessel.

That means the number of producing fields in the offshore will fall from four to three, and the hundreds of workers whose livelihoods are connected to the Terra Nova are now in doubt.

"There's only so much we can say. It's becoming very difficult to take care of our members," said Mercer.

The Terra Nova hasn't produced oil since it was ordered late last year to suspend operations by the board that regulates the offshore for a safety infraction.

There were hopesthat Suncor could resume production and carry out the refit at a later date, but sources say some partners were unwilling to spend the money required to recertify the Terra Nova, at a time when companies are slashing spending in order to manage through a collapse in the market.

Suncor was engaged in ongoing talks with the Canada-Newfoundland and Labrador Offshore Petroleum Board about a plan to restart production, but a resolution was never reached.

"As of yesterday we were still in very active discussions with Suncor on their recent proposal to resume production and thought those discussions were continuing," the C-NLOPB wrote in a statement to CBC.

"While we sympathize with the workforce affected by yesterday's announcement, we are not privy to the commercial considerations faced by Suncor and its partners."

Meanwhile, calls for the federal government to offer a lifeline to the oil sector continue.

"Wereally need is an investment in accelerating exploration in offshore Newfoundland and Labrador," said Coady.

The province and industry groups want Ottawa to offer tax breaks and other incentives to encourage oil companies to keep looking for new discoveries, similar to those offered in Norway and the United Kingdom.

Federal Natural Resources Minister Seamus O'Regansaid Wednesday he is in talks with the province and those in the industry.

"We are looking for options," said O'Regan, who specifically referenced "incentive-based exploration."

But O'Regan would not put a timeline on when those measures might be announced.

"We want to make sure we get it right," he said

Read more from CBC Newfoundland and Labrador

See original here:
As Suncor ponders Terra Nova's future, N.L. offshore workers worry about their own - CBC.ca

The Global Biaxially Oriented Polyethylene Terephthalate (BOPET) Film Market is expected to record a value of US$24.84 billion in 2024, growing at a CAGR of 6.83%, during 2020-2024. The factors such as rising demand for plastic packaging, accelerating manufacturing of electronic products, growth in digital printing, increasing retail sales of food and grocery, expansion of pharmaceutical industry and rapid urbanization are expected to drive the market growth. However, the growth of the market would be challenged by the heavy production cost of BOPET film and high prices of BOPET film. A few notable trends may include rising production capacity of flat panel display, rising growth of cosmetic products, development of biodegradable and water soluble films and rising awareness about the BOPET films.

The global BOPET film market is evolving rapidly over vast rates every year, owing to the continuous increase in its market demand. BOPET film has become a crucial component of every end-use sector due to the presence of versatile qualities. The BOPET striking features such as product quality, shelf life extension, high tensile strength and high durability make it an ideal product for packaging. The enormous application in packaging industry is the major reason for the BOPET film industry growth.

The fastest growing regional market was Asia-Pacific, due to the rapid urbanization, particularly in China and India. Rapid urbanization has led to the continuous changes in peoples lifestyles. Urban people have adopted a modern way of living, which contributed to the increase in BOPET film consumption as a premium product for various household purposes, including packaging. Therefore, Asia-Pacific has witnessed a modest growth in BOPET film market, which is further expected to contribute considerably to the global BOPET film market in coming years.

Scope of the report:

The report provides a comprehensive analysis of the global Biaxially Oriented Polyethylene Terephthalate (BOPET) film market.

The major regional and country markets (Asia-Pacific, Americas, Europe and ROW), along with the country coverage of China, India and North America have been analyzed.

The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.

The competitive landscape of the market, along with the company profiles of leading players (Toray Industries, Kolon Industries, Polyplex Corporation, Uflex Ltd., Jindal Poly Film Ltd. and Essel Propack) are also presented in detail.

Key Target Audience:

Plastic and Polyester manufacturers

Raw Material suppliers and distributors

End Users (food & beverage, pharmaceutical, E&E, imaging & graphics, etc.)

Investment Banks

Government Bodies & Regulating Authorities

Table of Contents

1. Overview

1.1 Introduction

1.2 Manufacturing Process of BOPET Films

1.3 Advantages of BOPET Film

1.4 Applications of BOPET Film

1.5 Importance of BOPET Film In Packaging

2. Global Market Analysis

2.1 Global BOPET Film Market by Value

2.2 Global BOPET Film Market Forecast by Value

2.3 Global BOPET Film Installed Capacity

2.4 Global BOPET Film Installed Capacity Forecast

2.5 Global BOPET Film Installed Capacity by Regions

2.6 Global BOPET Film Production Volume

2.7 Global BOPET Film Production Volume Forecast

2.8 Global BOPET Film Market Demand

2.9 Global BOPET Film Market Demand Forecast

2.10 Global BOPET Film Market Demand by Regions

3. Regional Market Analysis

3.1 Asia-Pacific

3.1.1 Asia-Pacific BOPET Film Installed Capacity

3.1.2 Asia-Pacific BOPET Film Installed Capacity Forecast

3.1.3 Asia-Pacific BOPET Film Installed Capacity by Regions

3.1.4 China BOPET Film Installed Capacity

3.1.5 China BOPET Film Installed Capacity Forecast

3.1.6 India BOPET Film installed Capacity

3.1.7 India BOPET Film Installed Capacity Forecast

3.1.8 Asia-Pacific BOPET Film Market Demand

3.1.9 Asia-Pacific BOPET Film Market Demand Forecast

3.1.10 Asia-Pacific BOPET Film Market Demand by Regions

3.1.11 China BOPET Film Market Demand

3.1.12 China BOPET Film Market Demand Forecast

3.1.13 India BOPET Film Market Demand

3.1.14 India BOPET Film Market Demand Forecast

3.2 Americas

3.2.1 Americas BOPET Film Installed Capacity

3.2.2 Americas BOPET Film Installed Capacity Forecast

3.2.3 Americas BOPET Film Installed Capacity by Regions

3.2.4 North America BOPET Film Installed Capacity

3.2.5 North America BOPET Film Installed Capacity Forecast

3.2.6 North America BOPET Film Production Volume

3.2.7 North America BOPET Film Production Volume Forecast

3.2.8 Americas BOPET Film Market Demand

3.2.9 Americas BOPET Film Market Demand Forecast

3.2.10 Americas BOPET Film Market Demand by Regions

3.2.11 North America BOPET Film Market Demand

3.2.12 North America BOPET Film Market Demand Forecast

3.2.13 North America BOPET Film Market Demand by Applications

3.2.14 North America Packaging & Metalizing BOPET Film Market Demand

3.2.15 North America Packaging & Metalizing BOPET Film Market Demand Forecast

3.2.16 North America Industrial BOPET Film Market Demand

3.2.17 North America Industrial BOPET Film Market Demand Forecast

3.2.18 North America Electrical & Electronic BOPET Film Market Demand

3.2.19 North America Electrical & Electronic BOPET Film Market Demand Forecast

3.2.20 North America Imaging & Graphics BOPET Film Market Demand

3.2.21 North America Imaging & Graphics BOPET Film Market Demand Forecast

3.3 Europe

3.3.1 Europe BOPET Film Market Demand

3.3.2 Europe BOPET Film Market Demand Forecast

3.4 ROW

3.4.1 ROW BOPET Film Market Demand

3.4.2 ROW BOPET Film Market Demand Forecast

4. Market Dynamics

4.1 Growth Drivers

4.1.1 Rising Demand for Plastic Packaging

4.1.2 Accelerating Manufacturing of Electrical and Electronic Products

4.1.3 Growth in Digital Printing

4.1.4 Increasing Retail Sales of Food and Grocery

4.1.5 Expansion of Pharmaceutical Industry

4.1.6 Rapid Urbanization

4.1.7 Environmental-Friendly

4.2 Key Trends and Developments

4.2.1 Rising Production Capacity of Flat Panel Display

4.2.2 Increasing Growth of Cosmetics Products

4.2.3 Development of Bio-Degradable and Water-Soluble Films

4.2.4 Rising Awareness about BOPET Packaging Films

4.3 Challenges

4.3.1 Heavy Manufacturing Cost of BOPET Films

4.3.2 High Prices of BOPET Films

5. Competitive Landscape

5.1 Global Market

5.1.1 Major BOPET Producers by Installed Capacity

5.1.2 Key Players Revenue Comparison

5.1.3 Key Players Market Capitalization Comparison

5.2 Indian Market

5.2.1 Key Players Business Model Competency Framework

See the original post here:
Global Biaxially Oriented Polyethylene Terephthalate (BOPET) Film Market (By Installed Capacity, Production, Demand and Region) : Insights, Trends and...

13 May 2020 --- Salt reduction remains high on the agenda for food manufacturers and brands tapping into increased demand for healthy products with a clean label. Under pressure following official recommendations from the World Health Organization (WHO) to drive down salt intake in the global population by 30 percent by 2025, food innovators face the ongoing challenges on lessening their reliance on sodium. This must be achieved, of course, without compromising on taste and delivering on health and wellness characteristics demanded by consumers who still expect the enrichment, complexity and premiumization in their savory choices with a low salt label.

Low sodium-based launches have grown considerably over the past five years, notes Innova Market Research, with a 7 percent average annual growth of food & beverage launches tracked with low/reduced sodium claims (Global, 2015-2019). Baby & Toddler foods have the highest percentage of launches with low/reduced sodium claims, citing the importance of salt reduction from an early age while Sauces & Seasonings and Soft Drinks are second and third, respectively. This is followed by Snacks (9 percent), Bakery (7 percent) and Cereals (6 percent).

While salt reducing focused NPD is obviously popular across various categories, taking away some of the standards from a manufacturers toolbox, such as salt, MSG and yeast extract, can create taste challenges.

Food manufacturers are now looking for solutions that allow them to reduce the sodium levels of their products, while also achieving the great taste and texture that consumers expect. It is, however, not only food producers who are increasingly aware of the importance of salt reduction in food public consciousness and awareness of the health impact of excess sodium has risen just as much, Mark Austin, Global Business Development Manager, DSM Food Specialties tellsFoodIngredientsFirst.

A recent DSM survey, which interviewed 5,000 people across 10 countries, found that 65 percent of respondents seek foods that contain less salt, while 71 percent and 66 percent of people questioned also reported looking for products that have lower levels of sugar and fat respectively.

This means that to really meet consumer needs for better-for-you products, producers must take a holistic approach to develop healthier options, considering not just salt reduction, but sugar and fat, too. The clean label movement has seen more consumers seeking products with shorter and more recognizable ingredient lists, with 71 percent of people in DSMs survey checking product labels and 66 percent buying goods made with ingredients they are familiar with, he continues.

When it comes to salt reduction, this means that producers must continue to look towards creating clean label solutions with reduced sodium content that appeal to consumers, Austin adds.

DSMs portfolio of yeast extract solutions for salt reduction can support food manufacturers in delivering healthy, tasty and appealing products. Yeast extracts are widely known for their rich savory taste profile, which can help producers create an authentic taste in low-sodium products. Part of DSMs sodium reduction toolbox, the Maxarome portfolio including Maxarome Select is ideally suited for a broad range of savory applications and can reduce salt levels in food, without compromising on taste or texture.

Suitable for both plant-based and meat dishes, these solutions have the ability to enhance the salty perception of goods, while delivering on umami, meaty or vegetable flavors, and masking off-notes and bitterness, notes Austin.

Processed food remains the leading contributor to salt intake in peoples diets. In industrial countries, approximately 75-80 percent of dietary salt is obtained through processed food, while 5-10 percent occurs naturally and the remaining 10-15 percent stems from salt that is added during cooking or at the table, continues Austin.

With the pressure from public health associations to reduce sodium intake continuing to grow, however, the need for manufacturers to adapt to ensure their product offering meets these demands is increasingly important, he says.

Click to Enlarge

Salt in the plant-based spaceSalt levels in plant-based products have recently come under scrutiny by UK organization, Action on Salt (AoS). It has recently published studies linking cutting salt helps support lower blood pressure which, it says, provide strong evidence for salt reduction as a major public health strategy for the UK which currently has voluntary salt reduction targets.

In the plant-based space specifically, AoS calls on the government to get tough on the eating out sector which lags far behind the food sold in retailers. This follows AoSs recent survey findings that show many healthy sounding plant-based and vegan meals served at UK restaurants, fast food and coffee chains, contain more salt than eight McDonalds hamburgers. Nearly half (45 percent) of meals eaten out of the home contain 3 g or more salt in just a single meal thats half the maximum daily limit for an adult. Additionally, over one in five dishes provide more than half an adults maximum daily recommendation for saturated fat.

Recognizing the demand for reduced salt in plant-based formulations, Roquette recently expanded its plant-based protein ingredient range that taps into the salt reduction trend. NUTRALYS L85M is a new specialty ingredient that further expands the existing range of NUTRALYS pea protein from Roquette. Beyond new tastes and new textures, Roquette will now offer its customers the ability to create plant-based meats with less salt to meet consumers demands and expectations when managing their daily sodium intake.

For Laura Queiroz Simon, Biorigin Global Product Manager, sodium reduction is no longer a trend, it is a confirmation of conscious consumption. She flags several categories that tap into convenience trends such as snacks and ready meals, as having a lot of opportunities to reduce the sodium content and to be more pressured by consumers and regulatory bodies.

Plant-based recipes tend to have a neutral taste profile and to compensate by giving more savory to these recipes the food companies are using salt. We know that consumers are aware and are pressuring the plant-based food industries to reformulate their recipes to reduce the salt and use clean label ingredients, she tells FoodIngredientsFirst.

The consumption is pushed by health concerns and consumers know that there is no point in consuming less meat in favor of plant alternatives if these recipes have a long list of ingredients with artificial additives and colors. Its well known that consumers avoid buying products with ingredients that are difficult to understand and are focusing on looking for products that contain ingredients perceived as natural, she says.

Meanwhile, Biorigin brings ingredients that help to reduce up to 50 percent sodium. Naturally rich in amino acids and nucleotides, there is a line of specific ingredients to promote the umami flavor the fifth basic flavor that brings a subtle and market sensation, increasing salivation and it is often perceived as a combination of sweet and salty flavors, allowing to compensate the salty taste loss and provide the overall recipe taste balance.

Bioenhance SFE 201 is designed to deliver a clean savory and umami notes, working in synergy with the recipe and compensating the sodium reduction. It is also able to mask off flavors when using different salts than Sodium Chloride (NaCl).

Biorigin offers a range of yeast extracts from standard savory to umami and roasted profiles to fulfill several applications and sodium reduction challenges and natural flavors that improve the salt perception with no sodium addition, maintaining the recipe taste profile, the company flags.

No need to compromiseFor Eelco Heintz, Product & Innovation Manager atNiacet, increasing consumer awareness of the harmful effects of excessive sodium consumption on health is driving demand for sodium reducing ingredients. At the same time, several countries have introduced legislation trying to tackle the issue. As a result, consumers are making a conscious effort to reduce sodium consumption and proactively checking sodium content on labels, he tells FoodIngredientsFirst.

As alternatives to the commonly used sodium-based preservatives gain ground, antimicrobials have an important role to play. There is no need to compromise between food safety and a healthy sodium content, he notes.

Next to sodium reduction there is an increased demand for shelf life extension and improved safety in a variety of food types, adds Heintz. Sodium-based preservatives are common, but there are preservation ingredients available that do not contain any sodium. Provian K, made with potassium salts, is one such example of a preservative that is proven to keep food safe and extend shelf life while reducing salt. Similarly, clean label solutions, such as Provian NDV, are made from naturally fermented vinegar and also contain no sodium, he explains.

Provian products are powdered organic acid-based preservatives, which makes it possible to simultaneously address both trends of salt reduction and increased shelf life.Originally, we focused on processed meat and poultry products, but this quickly expanded to other processed foods like fish, salads, spreads and a variety of ready-to-eat (RTE) products, Heintz notes.

Processed foods often contain a lot of salt, partly due to the high quantities of sodium-based preservatives used in them. However, by using high quality preservatives, manufacturers can create healthier products with lower levels of sodium. Preservatives such as Provian are highly effective at lower dosages, which will increase safety and extend shelf-life while reducing the amount of sodium in the final product, he says.

Not everyone is aware of the consequences of high salt intake. There are often cases of the public media warning against high salt intake, usually related to kidney or cardiovascular disease. Additionally, there is a clear trend visible of healthy and conscious living in the wider population. However, more can still be done, and it is obvious that awareness of sodium intake and a healthy sodium/potassium balance needs to be part of this trend, Heintz says.

Another category where salt reduction is an emerging trend is bakery. Baked goods substantially contribute to the daily sodium intake and a reduction is necessary to reach the goals set by governments and WHO. The industry has seen a voluntary reduction of sodium chloride content, but more still needs to be done. ProBake, from Niacet, offers world-leading standards in mold control with preservative options that contain no sodium, he adds.

Whats next?Rising demand for healthier, low-sodium food with a great taste and texture will continue to fuel product innovation and reformulation. Broader health trends will continue to drive thegrowing consumer trend for low-sodium clean label ingredients in their food. Consumers like the idea of products with easily identifiable ingredients, which can be difficult with preservatives as they often need to be labeled with a chemical name. However, preservatives made from natural ingredients can be used in products with natural claims and clean label ingredients. Niacets Provian NDV, for instance, is an effective clean label preservative, made from naturally fermented vinegar.

Manufacturers are searching for effective nutritional solutions for salt reduction that help them meet the trend for better-for-you food and stay ahead of the curve. Meanwhile, the continuing boom for plant-based products, innovation and R&D, will drive the need for more salt reducing solutions globally while more regulation is expected to be introduced around the world, forcing formulators who havent already done so to act.

By Gaynor Selby

To contact our editorial team please email us at editorial@cnsmedia.com

If you found this article valuable, you may wish to receive our newsletters. Subscribe now to receive the latest news directly into your inbox.

Visit link:
Salt reduction: Preservation without sodium and delivering on taste - FoodIngredientsFirst

Thanks to hours spent working from your couch, back-to-back Zoom happy hours or just staying idle while binging a new TV show, you may find yourself moving your body less than ever during the coronavirus pandemic. Since youre not exactly overexerting yourself these days, what gives?

The short answer is this: While you may be doing less physical activity, your brain has kicked into overdrive. In other words, the exhaustion you feel is not all in your head (or technically, in this case, it actually is.)

Although you may not be commuting to work, taking your weekly spin classes or spending weekends running errands, our drastically new coronavirus lifestyles can have a bigger impact on mental health and energy levels than we might think.

Ive probably been the most unproductive Ive ever been, said Madonna Matta, a 24-year-old graduate student from Austin, Texas. Im just tired all the time. I dont know if it may be the food Im eating more carbs, less veggies or the lack of structure, but I just feel melancholy.

Generally, exercising would make me feel more energetic and lively and now the opposite has made me sluggish, Matta continued. Sometimes, it feels easier to just sleep and pretend everything were living through is fake.

For Cathrine Nelson, a 27-year-old content creator in Providence, Rhode Island, the way she feels depends on the day.

I woke up at 8 a.m. the other day and had a full day, Nelson said. Another day, I slept in until 11 a.m., listened to some podcasts and went to bed early. Ive had productive days and almost completely inactive days. I feel like I am on a slow-motion roller coaster. I dont know when I am going to hit my next peak or my next drop.

bernardbodo via Getty Images

Why stress leads to so much fatigue

While certain stressors can be helpful for focusing and problem-solving like when you need to make a deadline or when youre driving and someone swerves in front of you they are meant to be temporary. The long-term stress we may feel as a result of COVID-19 and the constant flow of news about it is not to be underestimated, and it can exact wear and tear on the body.

People face challenges that really activate the sympathetic nervous system, so its kind of classic fight or flight response, said Craig N. Sawchuk, a psychologist at the Mayo Clinic. You get the hormone release to help keep us going like adrenaline and cortisol those are good. Its really adaptive that our body can flip that switch. But its not meant to be a constant burn, either. And thats where we run into these physical problems.

According to Sawchuk, when your brain is constantly trying to adapt to uncertainty, fear and challenges like it has during this entire pandemic it takes a toll over time. Your body physically gets tired from managing all the emotional stress.

And thats where you start to see some of the energy problems starting to happen where were fatigued, Sawchuk said. We may be actually resting a lot more, sometimes unintentionally so, but its not a restorative type of rest.

Energy expenditure extends beyond just physical activity. We burn up energy processing emotion, regulating our feelings, thinking, worrying and adapting to new challenges.

We think of physical, emotional and mental energy all drawing from that same pot, so we can think of multiple systems in our lives are constantly on and in turn, are constantly draining and wearing away at us, Sawchuk said.

Granger Wootz via Getty Images

How to boost your energy, even just a little

There are ways you can boost your energy at home and control stress levels. Johna Hansen, a licensed clinical social worker in New York City, recommended trying these steps:

Its uncertain how long COVID-19 will keep us in this state of lowered physical activity and heightened stress, but Sawchuk said resilience is key as we navigate the pandemic and the aftermath.

All of us as humans are resilient we really, really are, Sawchuk said. Resilience has this almost rubberized quality to it like bouncing back. But we will bounce back. It may not necessarily be to where we were at pre-COVID-19 because experience changes us; it changes the brain.

To Sawchuk, part of building resilience is learning to accept and adapt, which looks different for everyone. In other words, no one should be beating themselves up because they failed to make a sourdough starter or join an online yoga class that day.

We have to watch out when were making unfair comparisons to people that we think are just doing great, Sawchuk said. Our goal isnt to be perfect. Our goal is to be good enough. Being good enough is being kind to ourselves. There may objectively look like theres more time available, but thats not necessarily a good thing nor does it mean that were going to be more motivated or efficient. Its about adaptation.

A HuffPost Guide To Coronavirus

Read more here:
Why You Always Feel Tired, Even If You're Moving Less Than Ever - HuffPost

The report on the Thyroid Hormone Disorder Drug market provides a birds eye view of the current proceeding within the Thyroid Hormone Disorder Drug market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Thyroid Hormone Disorder Drug market and offers a clear assessment of the projected market fluctuations during the forecast period. The different factors that are likely to impact the overall dynamics of the Thyroid Hormone Disorder Drug market over the forecast period (2019-2029) including the current trends, growth opportunities, restraining factors, and more are discussed in detail in the market study.

The recent published research report sheds light on critical aspects of the global Thyroid Hormone Disorder Drug market such as vendor landscape, competitive strategies, market drivers and challenges along with the regional analysis. The report helps the readers to draw a suitable conclusion and clearly understand the current and future scenario and trends of global Thyroid Hormone Disorder Drug market. The research study comes out as a compilation of useful guidelines for players to understand and define their strategies more efficiently in order to keep themselves ahead of their competitors. The report profiles leading companies of the global Thyroid Hormone Disorder Drug market along with the emerging new ventures who are creating an impact on the global market with their latest innovations and technologies.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2551575&source=atm

The recent published study includes information on key segmentation of the global Thyroid Hormone Disorder Drug market on the basis of type/product, application and geography (country/region). Each of the segments included in the report is studies in relations to different factors such as market size, market share, value, growth rate and other quantitate information.

The competitive analysis included in the global Thyroid Hormone Disorder Drug market study allows their readers to understand the difference between players and how they are operating amounts themselves on global scale. The research study gives a deep insight on the current and future trends of the market along with the opportunities for the new players who are in process of entering global Thyroid Hormone Disorder Drug market. Market dynamic analysis such as market drivers, market restraints are explained thoroughly in the most detailed and easiest possible manner. The companies can also find several recommendations improve their business on the global scale.

The readers of the Thyroid Hormone Disorder Drug Market report can also extract several key insights such as market size of varies products and application along with their market share and growth rate. The report also includes information for next five years as forested data and past five years as historical data and the market share of the several key information.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2551575&source=atm

Global Thyroid Hormone Disorder Drug Market by Companies:

The company profile section of the report offers great insights such as market revenue and market share of global Thyroid Hormone Disorder Drug market. Key companies listed in the report are:

The following manufacturers are covered:Novo NordiskSanofiMerckEli LillyAstraZenecaAbbVie

Segment by RegionsNorth AmericaEuropeChinaJapanSoutheast AsiaIndia

Segment by TypeInjectionOralOthers

Segment by ApplicationHospitalClinicMedical CenterOthers

Global Thyroid Hormone Disorder Drug Market by Geography:

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2551575&licType=S&source=atm

Some of the Major Highlights of TOC covers in Thyroid Hormone Disorder Drug Market Report:

Chapter 1: Methodology & Scope of Thyroid Hormone Disorder Drug Market

Chapter 2: Executive Summary of Thyroid Hormone Disorder Drug Market

Chapter 3: Thyroid Hormone Disorder Drug Industry Insights

Chapter 4: Thyroid Hormone Disorder Drug Market, By Region

Chapter 5: Company Profile

And Continue

Read more:
The impact of the coronavirus on the Thyroid Hormone Disorder Drug Market Analysis Research and Trends Report for 2020-2029 3w Market News Reports -...

By: Taylor Roar, Capital News Service

Health professionals and federal agencies have expressed concern about the mental health effects of the global pandemic and social isolation. Mental health experts worry that there will be an uptick in stress-related disorders including depression, anxiety, substance abuse and post-traumatic stress disorder.

Though Congress is considering a bill to expand Medicare and Medicaid coverage of telehealth services from therapists and social workers in an attempt to begin tempering a possible mental-health crisis, mental health organizations still question the already-overwhelmed healthcare systems capacity to aid Americans when the quarantine is over.

Healthcare and government officials alike warn that a mixture of social distancing, exposure to death-related trauma, unemployment and other factors are expected to contribute to an increase of mental-health disorders among Americans for many years to come.

In the meantime, viral social media posts point to feelings that many people share.

For example, not knowing what day it is:

Or, the toils of trying to attend school from home:

And having to work alongside family members for the first time:

While hard data about the rates of mental illness during the pandemic are not yet available, there is plenty to suggest that people are looking for ways to cope with the excess of time that they are spending at home. According to Google Trends data, U.S. searches for the words positivity, self-care, baking and painting reached peak popularity in April.

There is scientific evidence that creating art has cognitive benefits. A growing body of research suggests that art therapy, or the practice of treating patients with mental health disorders with art-related activities, can reduce stress and anxiety as well asimprove symptoms of neurological and age-related disorderssuch as dementia and Alzheimers.

Researchers have foundthat painting, drawing, sculpting and even scribbling have the ability to stimulate the centers in the brain related to pleasure and reward. Psychotherapists, hospitals and schools across the country have adopted art therapy methods with positive results.

The practice has also been used on non-cognitive disorders. Mayo Clinics Slaggie Family Cancer Education Center offers art therapy to its patients. One of the reasons art therapy is helpful is because it can be used as a tool for self-expression and working through feelings; it is a way to convey emotions, hopes and concerns. While making art, the creative corner of the brain takes over, Megan Roessler, a staff member at the Slaggie Center,wrote in a blog post.

But if creating art is not your forte, similar benefits have been found for simply viewing art. Some researchers have found that browsing through an art gallery can help lower the bodys concentration of the stress hormone cortisol and increase that of the pleasure hormone dopamine.

While there may not be a way to physically access your favorite Smithsonian museum in the current climate, there is still plenty of art waiting to be viewed online. Some of the worlds most acclaimed museums are offering online access to some of their exhibits.The Louvreand theVatican Museumhave stunning virtual tours. Other museums, including theMetand theNational Gallery, are allowing visitors to access interactive photo galleries.

In addition, the hashtags#covidartand#covidartmuseumhave amassed more than 100,000 posts on Instagram. Artists from all over the world are connecting by sharing their creations via these hashtags. And you dont have to scroll far to find a piece thats relatable to what you may be going through.

Maybe youre feeling thankful for our healthcare workers:

Or looking for a way to escape the confines of your home:

Or reminiscing about that quarantine cut youre already regretting:

Or even laughing to keep from crying:

So consider picking up a paintbrush or viewing someone elses creations online. You may be surprised to find that art-related activities are effective stress relievers for you. Regardless,prolonged activation of the bodys stress system is harmful. There are countless other activities that have stress-relieving effects, including exercising and viewing nature. During this time, it is important to find ones that are effective for you.

This article is reprinted with permission from Capital News Serivce

The Southern Maryland Chronicle is a local, small business entrusted to provide factual, unbiased reporting to the Southern Maryland Community.While we look to local businesses for advertising, we hope to keep that cost as low as possible in order to attract even the smallest of local businesses and help them get out to the public. We must also be able to pay employees(part-time and full-time), along with equipment, and website related things. We never want to make the Chronicle a pay-wall style news site.

To that end, we are looking to the community to offer donations. Whether its a one-time donation or you set up a reoccurring monthly donation. It is all appreciated. All donations at this time will be going to furthering the Chronicle through hiring individuals that have the same goals of providing fair, and unbiased news to the community. For now, donations will be going to a business PayPal account I have set-up for the Southern Maryland Chronicle, KDC Designs. All business transactions currently occur within this PayPal account. If you have any questions regarding this you can email me at [emailprotected]

Thank you for all of your support and I hope to continue bringing Southern Maryland the best news possible for a very long time. David M. Higgins II

Read more here:
How art can help relieve stress during social isolation - The Southern Maryland Chronicle

Healthcare for a whole range of non-life-threatening illnesses, from dentistry to physiotherapy, has been put on hold since the outbreak of coronavirus in Ireland, in both the public and private health system. The Irish Times asked readers to tell us how they have been affected. This is a selection of the responses we received.

Due to the sensitive nature of health information, some names have been withheld on request.

I have found three lumps in my breast and have family history my mother has had breast cancer twice and my first cousin is just finished treatment for it. I had an appointment in St Vincents Private for March 26th and it was cancelled. Nobody can tell me when I will be able to get an appointment now. I have health insurance. Three lumps and a family history of breast cancer, and I am not seen as urgent. Sarah Donohoe

I went in for cataract removal in the Mater Private on February 20th. While the cataract was removed, the IOL (intraocular lens) wasnt inserted as the timeline to complete it ran out. It was rescheduled for March 19th but the HSE took over the hospital and my procedure was postponed. I am still waiting to be called by my consultant, but am giving it little/no hope as she is prevented from operating on private patients. I am in limbo and dont know what to do. I cannot see through my right eye. Tom Kennedy

I am 72 and my scheduled April knee replacement was cancelled because the Santry clinic was commandeered by the HSE. The private hospitals now have a 15 per cent bed occupancy and the public side have an abundance of beds. My surgeon informs me that I will be added to the bottom of the public waiting list (no complaint with that) and he is unsure if the private hospitals will ever reopen. The pre-Covid waiting time for an elective public joint replacement was four years (two years for a consultation and two years on the surgery list). If I stop paying the family VHI I could buy a golf buggy and cope with my golf, or pay for the surgery in another country like Romania. The only reason for having private health insurance is to cover whats not provided in any meaningful sense by the HSE - joint replacement, cataracts and benign surgery and if you get cancer, a heart attack or a stroke just rock up to hospital and you get immediate excellent treatment. Dr Michael Foley

Im from Cork. I suffer from chronic pain as a result of complications from numerous surgeries. At the end of last year I moved to Spain to access medical cannabis while waiting on the license at home that my GP and pain consultant applied for. My license was just approved this week in Ireland, however now I am stuck in Spain and unable to access medical cannabis here. Alicia Maher

Having suffered from thyrotoxicosis as a result of Graves Disease for almost two years, I was due to receive a thyroidectomy on March 31st. I had been advised by various consultants that definitive treatment was required, as my condition was not responding well enough to anti-thyroid medication to allow me to reduce the dosage. This medication is not considered safe to continue for longer than 18 months due to increased risk of side effects. I have now been consuming a high dose for 21 months.

On March 26th, my surgery was cancelled until further notice. I remained hopeful that if the hospitals did not become overwhelmed, it might soon be considered safe for my procedure to go ahead. In the meantime, I was advised to continue with my routine blood tests (every six weeks) and to now request that my liver function and full blood count be checked. This week, I received a letter from my endocrinologist stating that my surgery will not proceed until the Covid-19 situation has ended completely.

In addition to this, I also suffer from Graves ophthalmopathy as a result of my auto-immune thyroid condition. This creates numerous difficulties in my day-to-day life including pain, sleep disruption, and interference to my vision. I was referred to an ophthalmologist last November, and in February received my appointment letter, dated for June. When I attempt to call this ophthalmologists clinic, I am met with a pre-recorded message stating that the clinic is closed and that I should not leave a voicemail as it will not be received.

I am a private patient and all treatment has therefore been within the private healthcare system. While I felt that the decision to have the countrys private hospitals operate publicly during this crisis was a fair one, I feel my healthcare for a condition I am actually currently suffering from, is being sacrificed for the potential healthcare of those who may suffer from Covid-19 in the future.

I am now at my wits end; I feel the money I pay for health insurance is now putting me at a disadvantage. Necessary healthcare, which is my right, is being withheld despite the hospitals in Cork not being overwhelmed by Covid patients. Michelle ORegan

I was diagnosed with prostate cancer on March 6th, and told that treatment would be either a prostatectomy, or radiology combined with hormone therapy. The prostatectomy was apparently ruled out by the specialist, due to the coronavirus emergency. I had a telephone consultation with the radiologist, who made an appointment for a CT scan for March 31st at 9.45am. I arrived at the hospital at 9.15. I got a call from the specialist as I arrived to say that the procedure had been cancelled. He subsequently sent a letter to my GP, copied to me, which said I think it is safe to defer his treatment until later in the summer.

My four-year-old daughter needs two teeth removed via general anaesthetic. She has been given two antibiotics and is on a third from a urinary infection she got from the antibiotics. This is going on a month and a half now and she cannot eat with pain. We are told that dentists cannot use general anaesthetic at the moment due to Covid restrictions! I have spent the month on the phone going from pillar to post with dentists, the HSE, and politicians.

My GP referred me publicly and privately for colonoscopy and scope due to ongoing symptoms, unaware these procedures have all been cancelled.

Had an appointment for Cappagh Hospital for March 24th. Cancelled at five days notice. Still no update as to when it will happen.

I had an appointment for a knee replacement in April, which was cancelled. I am in pain and on daily medications. I cannot walk 50 metres now.

I was due to have surgery in Galway Clinic on March 23rd. I got a call on Friday 20th to say the surgery had been cancelled, as the clinic had to close. I am in serious pain on a daily basis. I pay VHI.

I spoke with my GP last Thursday, who requested a referral to the breast clinic. I got a letter today with an appointment for next Tuesday. It was super efficient.

I was given blood tests from the GP, since I had not been feeling well. I was told I had a deficiency of B12, which probably explains some depression and no energy. I was told I needed two injections a week for three weeks, then every three months. This was put on hold due to virus.

Only a small issue, but I had samples sent away a month ago to confirm a fungal infection. I have not heard back yet, have had no blood tests as I was told would take place within two weeks, and no updates from GP. My toe is in bad way, and I have to clean it daily and be careful with walking/ footwear so as not to pull at the nail or damage it.

I have recently been diagnosed with prostate cancer. I have had the treatment options explained to me but there is no treatment available for anyone with prostate cancer during the Covid emergency. My cancer is at an early stage, and I am not in urgent need of treatment. I fully understand that my case has to wait until the crisis is resolved. The oncologist has promised to contact me in July to review the situation. If there is still no prospect of treatment at that time I will begin to be worried.

I have been diagnosed with a neurological condition called CIDP. I cannot get an appointment to see my consultant neurologist in his rooms. Martina OFlaherty

I am due to have an arthroscopy and surgery to repair my rotator cuff in my right shoulder, and steroid injections in both knees for pain/arthritis.

I cannot get a scan either public or private. My doctor has sent requests too both. I had a surreal conversation from the Mater Private Cork, who phoned me to say they cannot see me as a private VHI patient, I then offered to pay them directly, to no avail. They also could not see me as a public patient. When I asked how could they see me. The receptionist who was very nice said they were only scanning patients who were put forward by specialists who worked for the Mater Private. I know you might think a sinus is a small thing in todays world, but this is seriously infected. I am popping antibiotics like theres no tomorrow.

I have a familial tendency to bowel cancer, which my father died from in his 60s. I am 68. I have had a number of colonoscopies in recent years and on each occasion have had a number of pre-cancerous polyps removed. My last one was in February 2019 after which the surgeon told me to come back in a year. I had an appointment arranged for March 24th, but all colonoscopies were cancelled from that day onwards. I recently received an appointment for sometime in July, but I understand that this is just a possibility and that the HSE have given the hospital no dates on which they may resume. I am worried.

My surgery was due in April at the Blackrock Clinic, cancelled due to private hospital takeover. I am very disappointed. It is not life or death, but with 2.2 million people with private insurance, the HSE is causing another crisis. Remove private work from public hospitals and leave the private sector alone.

Link:
Healthcare on hold: I cannot see through my right eye - The Irish Times

INTRODUCTION:

The hobnail variant of papillary thyroidcancer(PTC) is rare. Intrathyroid parathyroid adenoma (ITPA) is also rare. Co-ocurrence of PTC and ITPA in the same thyroid lobe is extremely rare. Likewise, primary hyperparathyroidism with such non-medullary thyroid carcinoma is rare. The specific molecular profile of hobnail PTC (HPTC) is different from the classic, poorly differentiated and anaplastic variants and may contribute to its aggressive behavior. HPTCs genetic profile remains unclear.

A 61-year-old woman presented to our endocrine clinic with generalized aches, bone pain, polyuria, and right neck swelling of a few months duration. Laboratory findings revealed hypercalcemia and hyperparathyroidism. Ultrasound of the neck showed 4.6cm complex nodule within the right thyroid lobe. Sestamibi scan suggested parathyroid adenoma in the right thyroid lobe. Fine-needle aspiration (FNA) revealed atypical follicular lesion of undetermined significance. She underwent right lobectomy, which normalized the intraoperative intact parathyroid hormone levels. Final pathology with immunohistochemical stains demonstrated HPTC and IPTA (2cm each). Next-generation sequencing investigated the mutation spectrum of HPTC and detected BRAFV600E mutation.

A parathyroid adenoma should not exclude the diagnosis of thyroid carcinoma. Thyroid evaluation is needed for patients with primary hyperparathyroidism to prevent missing concurrent thyroid cancers. Cytomorphologic features to distinguish thyroid from parathyroid cells on FNA cytology must be considered. Immunohistochemical stains are important. BRAFV600E is the most common mutation in HPTC. This is possibly the first reported case of HPTC and ITPA co-occurring within the same thyroid lobe. Studies that define other molecular abnormalities may be useful as therapeutic targets.

View original post here:
First ever case report of co-occurrence of hobnail variant of papillary thyroid carcinoma and intrathyroid parathyroid adenoma in the same thyroid...

Vaginas: they give us pleasure, cause us pain, and literally give us life. They're pretty damn amazing, but how well do you actually know yours?

Sexual wellness is a massive part of self-care, and the best way to look after yourself is to know exactly what's going on down there. And we're all different, so normal for you might not be for your mates. Nerding up on your nethers isn't only a good idea to help you get maximum enjoyment from masturbation and sex (although, that is a very good reason), but also so that you can easily spot the signs if something feels off.

Worryingly, it seems a lot of people are still mystified by the vagina and the vulva (the external part of the genitals). A 2019 YouGov poll found that 45% of women and 59% of men couldn't even point out the vagina on a diagram of female genitalia. They were also asked to point out the clitoris, which thankfully 71% of women, and 69% of men correctly identified. That's still almost one in three women who don't know where their clitoris is though yikes.

But now that we're in lockdown with a lot of time of our hands, why not spend some of it getting better acquainted with your vagina? GLAMOUR is here to get you clued up on your down there, busting myths and dropping some pretty amazing facts too. And we're not just talking about vaginas, either. We've got the lowdown on the ins and outs (so to speak) of your labia, clitoris, perineum, G-spot, even the A-spot (yes, it's a thing) the whole lot.

So pull up a chair, maybe grab a mirror and get ready to learn 20 amazing vagina facts. If this inspires you to indulge in a little self-care/love read our expert tips on orgasming on your own or check out our roundup of the best sex toys out there. You're welcome.

Link:
20 Facts You Need To Know About Your Vagina And Vulva - Glamour UK

Weight loss relies on a fairly straightforward equation: To drop the number on the scale, you must consume fewer calories than your body burns. With this in mind, it seems logical that cutting as many calories as possible can help you shed pounds faster. Makes sense, right?

News flash: Your weight-loss diet shouldn't leave you starving.

Image Credit: AndreyPopov/iStock/GettyImages

Hate to break it to you, but this calorie-slashing strategy may actually be sabotaging your efforts. In fact, eating too far below your specific calorie needs not only halts weight loss but may also negatively affect your health.

The rub is that everyone's calorie needs are different, so there's no one-size-fits-all when it comes to calorie counts for weight loss.

Here, Lisa Moskovitz, RDN, dietitian and founder of The NY Nutrition Group, helps you identify red flags that indicate you're not eating enough, plus offers guidance on how to determine the right number of calories you personally need for healthy, safe weight loss.

In general, women shouldn't cut their calories below 1,200 a day and men should stay above 1,500 unless they're under the supervision of a health care professional.

When you begin a weight-loss plan, your body might need time to adjust to eating fewer calories, so a hunger pang here or there is common. But if you're constantly craving your next meal or snack after a few days, something might be up.

"Thinking about food all the time is a sign your body needs more," Moskovitz says. That could mean more calories and/or a better balance of food groups to supply all necessary nutrients.

In other words, your diet might be lacking in major macros like carbohydrates, fats and proteins or other filling nutrients like fiber, which can keep your blood sugar stable and appetite in check.

That's why it's essential to heed your hunger cues. "Even if you think you ate enough based on specific portions, that doesn't mean your body agrees," Moskovitz says.

Lightheadedness is another indication that you're not eating enough. "Your blood sugars may be too low and thus causing you to feel weak or woozy," Moskovitz explains.

That's because when your blood sugar dips below what your body needs to function properly, your systems go into conservation mode to use less energy, according to Harvard Health Publishing.

This faint feeling may also be a result of dehydration, Moskovitz says. Without sufficient water, your blood volume decreases, leading to a decline in blood pressure, per Harvard Health Publishing. When this happens, your brain doesn't get enough blood, causing dizziness.

With that said, it's always a good idea to talk to your doctor if you experience these symptoms to be sure that you're not dealing with a more serious underlying health condition, Moskovitz says.

If your workouts are tougher than usual, you may need to evaluate what and how much you're eating.

Image Credit: Tero Vesalainen/iStock/GettyImages

Wiped out during workouts? Poor performance in the gym is a hallmark of consuming too little food, Moskovitz says.

Here's why: Calories equal energy, so if you're not ingesting an adequate amount, your body must use all its strength to support basic functions and it won't have much oomph left over for anything extra, including your workouts.

Not only does undereating sap your energy, it also curbs your ability to build lean muscle, Moskovitz adds. Since muscle burns more calories than fat, even at rest, having more of it aids weight loss.

Remember, to gain muscle, you need to pack plenty of protein onto your plate, per the American College of Sports Medicine. If you're over-restricting calories, though, odds are you're not getting enough of the macronutrient.

If you're in a calorie deficit, you should be aiming for 1.3 grams of protein per kilogram of body weight (a kilogram is about 2.2 pounds, for the record).

A diet that's too low in calories can leave you backed up.

"Not eating enough means there is nothing to push through your digestive tract, which can lead to bowel movement irregularities such as constipation," Moskovitz says.

Plus, a lot of trendy diets ditch (or significantly cut) carbs including healthy whole grains, veggies and fruits which are full of fiber. The thing is, fiber bulks up your poop and helps food pass from your stomach to your intestines, per the U.S. National Library of Medicine. So, without enough of it, your stool gets, well, sort of stuck.

To avoid this and speed up your stool, Moskovitz recommends eating at regular intervals throughout the day with plenty of gut-healthy fiber as well as hydrating with water to keep things moving smoothly.

Psst: A study published February 2015 in the Annals of Internal Medicine found that simply aiming to eat 30 grams of fiber each day could help you lose weight as effectively as a more complicated diet.

If your weight loss grinds to a halt, you might think that slashing more calories is the solution. It's probably not.

Though it sounds counterintuitive, your low-calorie diet could be the reason you've stopped shedding pounds in the first place.

"Whenever you limit calories to lose weight, your metabolism can go through a process called adaptive thermogenesis," Moskovitz says. When this happens, your metabolism may slow down.

Essentially, when you cut too many calories, your body goes into survival mode, so it burns fewer calories to preserve energy. In short, your body is protecting you from what it perceives as starvation.

To make matters worse, restrictive dieting may even raise your levels of cortisol, a stress hormone linked to increased appetite and belly fat, according to a May 2010 study published in Psychosomatic Medicine.

Too-few calories can leave your immune system in the lurch.

Image Credit: PeopleImages/E+/GettyImages

Catching colds regularly? Your low-calorie diet may be to blame.

"Eating too little can negatively affect the immune system and stress out the body," Moskovitz says.

When this happens, your body produces fewer lymphocytes, aka infection-fighting white blood cells, according to the Cleveland Clinic. Consequently, with lower lymphocyte levels, you run a greater risk of getting sick.

What's more, restrictive dieting "usually means you're not getting key immune-building nutrients like vitamin C, zinc, vitamin D and probiotics," Moskovitz adds.

Put simply, your body's defenses suffer when you cut too many calories in the form of wholesome, nutritious foods.

First, determine the number of calories you should be eating each day to maintain your weight by using the chart in the Dietary Guidelines for Americans, which breaks it down by age, sex and physical activity level.

For healthy weight loss (about 1 pound per week), you should aim to cut about 500 calories a day from that amount, according to the Mayo Clinic. (As long as you're not falling below 1,200 calories for women or 1,500 calories for men.)

To make it even easier on yourself, you can download LIVESTRONG.com's MyPlate tracker, which will do the calculating for you. The app also makes it easy to update your needs as your weight and exercise regimen change.

Moskovitz suggests consulting with a registered dietitian, who can take a look at your complete medical, lifestyle and diet history. A nutrition expert can also help you devise a proper meal plan to ensure you get the nutrients you need when cutting calories.

Link:
6 Signs Youre Not Eating Enough Calories on Your Weight-Loss Diet - LIVESTRONG.COM

InForGrowth Market Research offers a most recent distributed report on Global Adenomyosis Treatment industry examination and figure 2019-2025 conveying key bits of knowledge and giving an upper hand to customers through a point by point report. The report contains XX pages which profoundly displays on current market investigation situation, up and coming just as future chances, income development, evaluating and gainfulness. The Global pandemic of COVID19 calls for redefining of business strategies. This Adenomyosis Treatment Market report includes the impact analysis necessary for the same

Download Sample Table of Content PDF of COVID-19/CoronaVirus Impact Analysis of Adenomyosis Treatment Market 2020. https://inforgrowth.com/CovidImpact-Request/6322440/adenomyosis-treatment-market

Worldwide Adenomyosis Treatment Market inspect reports consolidate market designs nuances, genuine scene, feature assessment, cost structure, capability, bargains, net advantage, and movement and measuring of business.

Major Key players covered in this report:Bayer AG, Ferring B.V, Johnson & Johnson, Novartis, Merck, Pfizer, Contura.

Adenomyosis Treatment Market Potential

The overall market is set up for energetic advancement with progressively moving of various gathering methodology to more affordable objectives in rising economies. Another factor booked to altogether bolster the market is fused programming game plans disposing of the prerequisite for different models and thing survey concerns.Premium Insights on Adenomyosis Treatment Market 2020 with Market Players Positioning; Download Free Sample Copy: https://inforgrowth.com/sample-request/6322440/adenomyosis-treatment-market

The Worldwide Market forGlobal Adenomyosis Treatment marketis relied upon to develop at a CAGR of generally xx% throughout the following five years, will arrive at xx million US$ in 2026, from xx million US$ in 2019, as per another research.

This report focuses around the Adenomyosis Treatment Market in the worldwide market, particularly in North America, Europe and Asia-Pacific, South America, Middle East, and Africa. This Adenomyosis Treatment Market report sorts the market dependent on the manufacturer, region, type, and application.

Major Classifications of Adenomyosis Treatment Market:

By Applications: Hospital, Clinic, Others

The study objectives of Adenomyosis Treatment Market Report are:

Regional Analysis of Adenomyosis Treatment Market:

The report additionally provides a local examination of the market with a high focus on showcase development, development rate, and development potential. The research report calculates marketplace length estimation to analyze investment possibilities and destiny growth. The key players and distinctive affecting components are examined completely on this report.

Enquire before Purchase this report at https://inforgrowth.com/enquiry/6322440/adenomyosis-treatment-market

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:Address: 6400 Village Pkwy suite # 104, Dublin, CA 94568, USAContact Name: Rohan S.Email:[emailprotected]Phone: +1-909-329-2808UK: +44 (203) 743 1898Website: http://www.inforgrowth.com

Read more here:
Adenomyosis Treatment Market 2020: Potential Growth, Challenges, and Know the Companies List Could Potentially Benefit or Loose out From the Impact of...

DUBLIN--(BUSINESS WIRE)--The "Global Stem Cell Therapy Market By Type (Allogeneic, Autologous, Syngeneic), By Source of Stem Cells (Adipose Tissue, Bone Marrow, Neural, Embryo/Cord Blood derived, iPSCs, Others), By Application, By End Users, By Region, Forecast & Opportunities, 2025" report has been added to ResearchAndMarkets.com's offering.

The Global Stem Cell Therapy Market is expected to grow at a formidable rate of around 12% during the forecast period. The industry is segmented based on type, source of stem cells, application, end-users, company and region.

The market is driven by the growing popularity and awareness pertaining to the use of stem cells for the prevention and cure of certain life threatening diseases. Additionally, increase in number of stem cell banks and growing investments by the government and private organizations for the development of stem cell preservation infrastructure is further propelling the market across the globe.

Based on type, the market can be categorized into allogeneic, autologous and syngeneic. The allogenic type segment is expected to register the highest growth during forecast period attributable to the rising commercialization of allogeneic stem cell therapy products, wider therapeutic applications of allogeneic stem cells, easy production scale-up process, growing number of clinical trials related to allogeneic stem cell therapies, among others.

Based on end-users, the market can be bifurcated into hospitals and clinics. The hospitals segment is expected to dominate the market during the forecast years. This can be accredited to the rising preference for stem cell therapies offered by hospitals proves beneficial for the business growth. Hospitals have affiliations with research laboratories and academic institutes that carry out research activities for developing stem cell therapies. On introduction and approval of any novel stem therapy, hospitals implement it immediately.

Regionally, the stem cell therapy market has been segmented into various regions namely Asia-Pacific, North America, South America, Europe, and Middle East & Africa. Among these regions, North America is expected to dominate the overall stem cell therapy market during the next five years on account of the increasing number of clinical trials for stem cell-based products and increasing public-private funding & research grants.

Major players operating in the Global Stem Cell Therapy Market include Osiris Therapeutics, Inc., MEDIPOST Co., Ltd., Anterogen Co., Ltd., Pharmicell Co., Ltd., Holostem Terapie Avanzate S.r.l., JCR Pharmaceuticals Co., Ltd., NuVasive, Inc., RTI Surgical, Inc., AlloSource, Thermo Fisher Scientific and others. The companies are developing advanced technologies and launching new services in order to stay competitive in the market.

Years considered for this report:

Objective of the Study

Key Topics Covered

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Global Stem Cell Therapy Market Outlook

5.1. Market Size & Forecast

5.1.1. By Value

5.2. Market Share & Forecast

5.2.1. By Type (Allogeneic, Autologous, Syngeneic)

5.2.2. By Source of Stem Cells (Adipose Tissue, Bone Marrow, Neural, Embryo/Cord Blood Derived, iPSCs, Others)

5.2.3. By Application (Musculoskeletal, Wound & Injury, Cardiovascular Disease (CVD), Surgery, Acute Graft-Versus-Host Disease, Drug Discovery & Development, Others)

5.2.4. By End Users (Hospitals v/s Clinics)

5.2.5. By Company (2019)

5.2.6. By Region

5.3. Product Market Map

6. Asia-Pacific Stem Cell Therapy Market Outlook

7. Europe Stem Cell Therapy Market Outlook

8. North America Stem Cell Therapy Market Outlook

9. South America Stem Cell Therapy Market Outlook

10. Middle East and Africa Stem Cell Therapy Market Outlook

11. Market Dynamics

11.1. Drivers

11.2. Challenges

12. Market Trends & Developments

13. Competitive Landscape

13.1. Osiris Therapeutics, Inc.

13.2. MEDIPOST Co. Ltd.

13.3. Anterogen Co. Ltd.

13.4. Pharmicell Co. Ltd.

13.5. Holostem Terapie Avanzate S.r.l.

13.6. JCR Pharmaceuticals Co. Ltd.

13.7. NuVasive, Inc.

13.8. RTI Surgical, Inc.

13.9. AlloSource

13.10. Thermo Fisher Scientific

14. Strategic Recommendations

For more information about this report visit https://www.researchandmarkets.com/r/hmawq6

Here is the original post:
Global Stem Cell Therapy Market Forecast & Opportunities, 2025 - ResearchAndMarkets.com - Business Wire

MIKE TYSON has been doing the rounds to physically prepare for his sensational boxing comeback aged 53.

Tyson, who retired in 2005, has a whole new diet and cardio regime as well as going through a "weird" stem cell treatment.

3

It comes after the former heavyweight king announced plans to make a return to the ring to compete in exhibition bouts for charity, and has been training for the last month to do so.

Speaking to rapper LL Cool J on the Rock the Bells Radio show on SiriusXM, Tyson explained the methods he is using to get back into fighting shape, as he revealed: "Really I would just change my diet and just do cardio work.

"Cardio has to start, you have to have your endurance to go and do the process of training.

"So something to do is get in cardio, I would try and get two hours of cardio a day, make sure you get that stuff in. Youre gonna make sure youre eating the right food.

"For me its almost like slave food. Doing what you hate to do but doing it like its nothing. Getting up when you dont want to get up.

"Thats what it is. Its becoming a slave to life.

"Being a slave to life means being the best person you can be, being the best you can possibly be, and when you are at the best you can possibly be is when you no longer exist and nobody talks about you. Thats when youre at your best."

Tyson's return to training for the first time in 15 years has been aided by stem-cell research therapy, that has left him feeling like a "different person".

Stem-cell therapy is the use of stem cells to treat or prevent a disease or condition that usually takes the form of a bone marrow transplantation.

Tyson was asked whether that meant if his white blood had been spun and then put back in, to which he replied: "Yes. As they took the blood it was red and when it came back it was almost transfluid (sic).

"I could almost see through the blood, and then they injected it in me.

"And Ive been weird ever since, Ive got to get balanced now."

Having previously claimed he feels in the best shape of his life, Tyson revealed he will be ready to fight again in just six weeks.

He said: "My mind would belong to somebody that disliked me enough to break my soul, and I would give them my mind for that period of time.

"Six weeks of this and Id be in the best shape Ive ever dreamed of being in. As a matter of fact, Im going through that process right now. And you know what else I did, I did stem-cell research."

WHAT IS STEM CELL TREATMENT USED FOR?

Stem cell transplants are carried out when bone marrow is damaged or isnt able to produce healthy blood cells.

It can also be used to replace damaged blood cells as the result of intensive cancer treatment.

Here are conditions that stem cell transplants can be used to treat:

GARDEN PARTYEddie Hearn reveals plan to bring boxing back by hosting fights in his GARDEN

NO W-HAYEHaye snubs Mike Tyson in top 5 heavyweights of all time and details sad decline

Revealed

MONEY MIKEMike Tyson's earnings from all his major fights revealed as he raked in 557m

Exclusive

SON OF A GUNTeddy Atlas lost 30m after holding gun to Mike Tyson's head when he was 15

BLOOD SPORTMike Tyson injected by docs with translucent blood that made him feel 'weird'

WEATHER THE STORMMayweather demands 500MILLION to make stunning boxing return

TONE IT DOWNTyson Fury is No1 in world but Anthony Joshua would beat him says Bellew

GYPSY SWINGFury names his next THREE fights as he refuses to pay Wilder to step aside

Rich MikeWhat is Mike Tyson's net worth and how does he earn cash now?

During his reign as champion, Tyson would wake up at 4.30am to run before later heading to the gym where he would do 10-12 rounds of boxing mixed in with an array of muscles exercises.

His diet consisted of 3000-4000 calories of carbohydrates and proteins which helped fuel his training sessions.

Tyson, still the youngest heavyweight champion of all time at 20, retired with a record of 50-6-2 and remains one of the most celebrated punchers of all time.

3

3

Read the original post:
How Mike Tyson is in such incredible shape at 53 thanks to new diet, cardio and weird stem cell tre - The Sun

Brian Lindberg

Lockheed Martin Corporation has partnered with Be The Match to enable patients to continue receiving life-saving transplants without interruption during the COVID-19 pandemic by ensuring the timely delivery of bone marrow and blood stem cells for transplant, Lockheed Martin reported on Thursday.

"The incredible support from Lockheed Martin is a lifeline to our patients. For those awaiting bone marrow transplant, their very survival depends on the on-time delivery of these life-saving cells. By offering flight services, Lockheed Martin is helping us ensure that patients can continue the cells they need, exactly when they need them," said NMDP/Be The Match Chief Policy Officer Brian Lindberg.

With Lockheed Martins donation of the companys corporate aircraft, the National Marrow Donor Program (NMDP)/Be The Match was able to support the federal government's COVID-19 response and relief efforts and ensure patients that life-saving products from European donors would arrive on time.

Under the partnership, Lockheed Martin will provide weekly air transport based on government medical need. The company will fly government medical teams to the most critical, high-priority locations around the country. In addition, Lockheed Martin will transport materials to support bone marrow transport to help with the government's COVID-19 response.

In addition to matching donors and patients, one of the program's primary missions is coordinating the delivery of bone marrow domestically and internationally to patients in the United States and abroad.

Marillyn Hewson, CEO, chairman and president of Lockheed Martin and 2020 Wash100 Award recipient, recently released the companys efforts to remediate the effects of the global pandemic. In April 2020, Hewson noted that Lockheed Martin has projected that it will be able to flow down over $450 million in accelerated payments to its supply chain partners.

The funding will support those who are critical to supporting the economy and national security. Lockheed will continue its work with the Department of Health and Human Services and provide air transport of government medical teams to the most critical, high-priority locations around the country. The company also pledged $10 million in charitable contributions for COVID-19 relief and recovery efforts.

The company has donated $2 million to Project HOPE to help deliver personal protective equipment to the Federal Emergency Management Agency for distribution to America's doctors, nurses, and first responders. Lockheed also donated $2 million to the American Red Cross to support military personnel, veterans, and families and $2 million to the CDC Foundation All of Us to combat Coronavirus emergency response fund.

As we continue to face this unprecedented crisis, Lockheed Martin is driven by our commitment to the mission of our U.S. and allied customers. We will continue to maintain our operations for our men and women in uniform and we are resolved to find additional ways to contribute to the relief and recovery from COVID-19, Hewson noted.

About Lockheed Martin

Headquartered in Bethesda, Maryland, Lockheed Martin is a global security and aerospace company that employs approximately 110,000 people worldwide and is principally engaged in the research, design, development, manufacture, integration and sustainment of advanced technology systems, products and services.

Read more here:
Lockheed Martin Partners with Be The Match to Expedite Delivery of Transplants During COVID-19 Pandemic; Brian Lindberg Quoted - ExecutiveGov